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ABSTRACT
Brucella is a genus of Gram negative, facultative intracellular pathogens which cause
brucellosis, one of the most wide spread zoonotic diseases. Brucellosis causes a severe
economic burden due to reproductive loss in animals and human infection. Vaccination of
animals has proven to be the most effective means of controlling brucellosis; however the current
live-attenuated vaccines are not considered ideal. The live-attenuated vaccines Brucella abortus
Strain 19 and RB51 remain pathogenic to humans, and the former interferes with diagnostic tests
due to induction of antibodies against the O-polysaccharide. DNA vaccination with single
antigens has proven to be successful at protecting mice against B. abortus challenge, however
this method is less effective in large animals. Immunization with a combination of antigens has
been shown to provide more protection than single antigens.
In an attempt to develop a better DNA vaccine, two multivalent multi-epitope plasmids
were constructed using known protective antigens and bioinformatics technologies. Epitopes
predicted to induce cell-mediated immunity were selected from Cu/Zn superoxide dismutase,
outer membrane protein (Omp) 16, Omp19, ribosomal subunit L7/L12, BP26, ribosomal subunit
L9, and Omp25. The plasmids were transfected into Chinese hamster ovary (CHO K1) cells, and
PCR was used to confirm presence of the sequences in the genome. The transcription of the
BabV1 and BabV2 genes to RNA was confirmed using RT-PCR. Finally, Western blots using
sera from Strain 19 infected goats suggest the protein is not recognized by the humoral response
of vaccinated animals. Further research is required to determine if the p425/BabV1 and
p425/BabV2 vaccines are recognized by the cell-mediated immune response of infected or
vaccinated animals.

viii

CHAPTER I
LITERATURE REVIEW
INTRODUCTION
Brucella is a genus of Gram negative, facultative intracellular pathogens which cause
brucellosis, one of the most widespread global zoonotic diseases [1, 2]. Infection in cattle causes
abortion and infertility; and in humans, undulant fever, arthritis, endocarditis and spondylitis [3,
4]. The Brucella spp. are named based on their natural host with B. melitensis for goats, B.
abortus for cattle, B. suis for swine, B. canis for dogs, B. ovis for sheep, and B. neotomae for
desert mice [5]. Smooth Brucella species express full lipopolysaccharide (LPS) molecules,
while rough Brucella spp. lack O-polysaccharide antigen (OPS) of the LPS [6, 7]. The brucella
OPS is a homopolymer of 100 residues of 4-formamido-4, 6-dideoxymannose linked by
predominately α-1,2 bonds in A epitope strains or α-1,3 bonds every fifth residue in M epitopes
strains [8]. Brucella spp. are aerobic, fastidious, slow growing, and require supplemental CO2,
thiamine, nicotinamide, biotin, and serum for growth [9, 10].
Humans may be exposed by ingestion of unpasteurized milk from infected animals;
contact with infected tissue, blood, lymph; or inhalation of aerosols [2, 6, 11]. Globally, there
are approximately 500,000 cases of human brucellosis reported each year resulting in high
economic burdens due to animal brucellosis in developing countries [12, 13]. One of the most
effective means of controlling brucellosis, in both humans and animals, is vaccination of animals
[14, 15]. The live-attenuated vaccines B. abortus Strain 19 and rough B. abortus Strain 51
(RB51) grant protection against abortion and infection caused by B. abortus in cattle, and the
live-attenuated vaccine Rev. 1 protects against B. melitensis in goats and sheep [5, 14]. Though
they are effective in protecting against brucellosis, these are not considered ideal vaccines due to
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residual virulence in humans; ability to cause abortion in pregnant animals; and in smooth
strains, such as Strain 19 and Rev. 1, induction of anti-OPS antibodies that interfere with
serological tests [14, 16]. There is currently no vaccine available for use in humans or wildlife
reservoirs [17].
The goal of this research project was to determine if it is possible to design a DNA
vaccine recognized by the humoral immune response of vaccinated animals. A combination of
literature mining and bioinformatics technologies was used to select protective epitopes against
B. abortus infection. Plasmids coding for these epitopes were constructed and transfected into
Chinese hamster ovary (CHO K1) cells. The CHO K1 genome was then analyzed via PCR to
determine the presence of the vaccine sequences. Transcription of the vaccine sequence into
RNA was determined via RT-PCR. Finally, media and cell lysate from the CHO K1 cells were
analyzed via Western blot using Strain 19 vaccinated goat sera to detect the recombinant
proteins.
ADAPTIVE IMMUNE RESPONSE
The immune system is divided into the innate and adaptive systems [18]. The innate
immune system is the first line of defense against infection and has no immunological memory
[18]. On primary exposure, the adaptive immune system develops a specific memory response
that is recalled on subsequent exposures [18]. The adaptive immune system is divided into cellmediated, which consists of CD4+ and CD8+ T cells, and humoral immunity, which consists of
B cells and antibodies. Vaccines induce an adaptive immune response which is recalled on
secondary exposure. During the development of an adaptive cell-mediated response, naïve
CD4+ and CD8+ T cells differentiate and proliferate when stimulated by cytokines,
costimulatory molecules, and antigen presenting cells (APC) displaying an epitope in the context
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of Major Histocompatibility Complex (MHC) molecules recognized by the T cell receptor [19,
20]. The cytokines and costimulatory molecules that the naïve T cells are exposed to during
differentiation determine the effector function of the differentiated cell [19, 21]. A number of
these differentiated T cells become memory cells which are recalled rapidly on secondary
exposure [22].
Interleukin-12 (IL-12) causes naïve CD4+ cells to differentiate into Type 1 T helper
(Th1) cells which secrete IL-18, IL-2, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ)
[19, 23]. The latter three cytokines are capable of activating macrophages and CD8+ cells to kill
intracellular pathogens, such as Brucella spp. [19]. Type 2 T helper (Th2) cells are differentiated
by IL-4 stimulation and secrete IL-4, IL-5 and IL-10 [19]. Th2 cells promote antibody, primarily
IgG1 and IgE, production by B cells and are therefore considered to be a regulator of the
humoral immune response [19]. In addition, IL-2 promotes T cell proliferation and survival; and
is important for both Th1 and Th2 differentiation [23-25]. Th17 cells are produced when naïve
CD4+ T cells are stimulated by both IL-6 and transforming growth factor-β (TGF-β) and secrete
IL-17 [19]. IL-17 is able to activate various cell types to produce pro-inflammatory cytokines
and molecules such as IL-6, IL-1β, TNF-α, and nitric oxide (NO) [26].
CD8+ cells kill infected host cells through secretion of granzyme and perforin as well as
secretion of cytokines such as TNF-α and IFN-γ [21, 27]. Although the exact mechanisms are
unclear, establishment of memory CD8+ cells and their effector function upon secondary
exposure depends on CD4+ T cell help, antigen avidity, and cytokine stimulation [21, 24, 25].
Indeed, CD8+ cells that differentiate in the absence of CD4+ cells during primary infection show
reduced proliferation and cytokine secretion [21, 25].
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Major Histocompatibility Complex are a class of molecules which bind to and present
processed peptide epitopes on the surface of cells for T cell recognition [28, 29]. Epitopes, also
known as antigenic determinants, are the minimum essential portions of antigens recognized by
the immune system [27, 30]. Linear epitopes are epitopes with amino acid residues adjacent in
sequence [31], while conformational epitopes are formed by residues that are discontinuous but
close in three dimensional space [32]. MHC I molecules are displayed on the surface of all
nucleated cells and present endogenous linear epitopes that are 8-11 amino acids (mostly
nonamers) long to CD8+ T cells [27, 29, 33]. MHC II molecules are displayed on the surface of
APCs and present exogenous 13-30 amino acid long epitopes to both CD4+ T cells (linear
epitopes) and B cells (linear and conformational epitopes) [27, 33, 34].
TH1 RESPONSE
Resistance to brucellosis is primarily mediated by a Th1 immune response, mainly due to
IFN-γ activation of macrophages [5, 17, 35-38]. CD4+ and CD8+ T cell subsets have also been
shown to be involved in resistance against infection by production of cytokines, such as IFN-γ
and TNF-α, and cytotoxic killing of infected macrophages [5, 17, 27, 35, 37-43]. Studies on the
depletion and passive transfer of T cell subsets have revealed that both CD4+ and CD8+ cells
contribute to resistance, and protection is greater when both subsets are present [39, 40].
Exogenous IL-2 in culture with B. abortus Strain 19, Strain RB51, and virulent Strain 2308
infected macrophages reduced the replication of bacteria at 24 hours but not at 48 hours [42].
However, addition of IL-2 to IFN-γ activated macrophages neither enhanced nor inhibited
control of infection [42].
Both CD4+ and CD8+ produce IFN-γ in response to brucella infection [37]. IFN-γ is
crucial for the control and clearence of brucellosis in the animal model [37, 38, 44]. IFN-γ
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enhances resistence by increasing the production of reactive oxygen species (ROS) by
macrophages, and the amount of IFN-γ produced by both murine CD4+ cells and splenocytes
correlates with resistance to brucellosis [38]. Exogenous IFN-γ in macrophage culture increased
anti-brucella activity, including increased ROS production. and reduced replication in the
infected IFN-γ activated macrophages [38, 42, 44]. IFN-γ neutralization by anti-IFN-γ
monoclonal antibodies (mAb) and IFN-γ gene knock out mice show increased splenic colony
forming units (CFU) in both naturally susceptible BALB/c and naturally resistant C57BL/6 mice
one week post infection [38, 43, 44]. Both resistant and susceptible IFN-γ knock out mice die by
six and 12 weeks post infection, respectively [38]. Resistant mice produce IFN-γ at all measured
time points during infection, while susceptible mice stop producing IFN-γ between weeks three
and six [38]. During this IFN-γ hiatus CD8+ cells and TNF-α control the infection, but are
unable to clear brucellae from the animal [38].
Tumor necrosis factor-α enhances resistance to brucella infection during the first two to
three weeks of infection in both wild type (WT) and IFN-γ knock out mice [43, 45] however,
splenic CFU in TNF-α deficient mice were similar to control mice by six weeks post infection
[45]. In both the presence and absence of IFN-γ, TNF-α has been shown to enhance macrophage
killing of Brucella spp., but it is not able to clear brucella infection in vivo [38, 43, 46]. Further,
mice deficient in TNF receptors (TNFR-/-) were less able to control brucellosis and produced
neglible quantities of IL-12 from splenic cells of Strain 19 infected C57BL/10 mice in the first
two weeks of infection [47], suggesting that TNF-α indirectly promotes the development of a
Th1 response [45]. These data suggests that TNF-α plays both a direct and indirect role in
resistance to brucellosis in the animal model.
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TH2 RESPONSE
The contribution of IL-4 to brucellosis susceptibility is controversial [48, 49]. The
addition of exogenous IL-4 to IFN-γ activated macrophages did not inhibit or enhance control of
brucella infection in vitro [42]. IL-4 deficient C57BL/6 mice, but not BALB/c mice, are more
resistant than WT to B. melitensis when analyzed on days 5, 12 and 28 post infection [48].
However, IL-4 deficient BALB/c do not show enhanced resistance at these time points [48]. IL4 neutralization with mAb reduces the splenic CFU of less virulent B. abortus Strain 2308 from
both BALB/c and C57BL/10 mice but only at lower challenge doses [49]. IL-4 is also an
important survival factor for B cells thus generating an antibody response [50]. IL-4
neutralization reduced antibody production and indirectly promoted a Th1 response [49]. This
suggests that the deleterious effects of IL-4 are mediated by inhibition of Th1 development and
not directly on macrophage killing of Brucella organisms.
Interleukin-10 has been shown to increase susceptibility to brucellosis in the mouse
model [17, 38, 44, 49]. BALB/c mouse splenocytes and B cells produce significant amounts of
IL-10 after infection with B. abortus [37, 38]. Addition of IL-10 to brucella-infected
macrophage cultures reduced control of infection both in the presence and absence of exogenous
IFN-γ [44]. Interleukin-10 is also known to suppress IL-12 production, indirectly suppressing
the Th1 response and IFN-γ production [44, 51, 52]. Taken together, this indicates IL-10 both
directly and indirectly increases susceptibility to brucellosis.
TH17 RESPONSE
The Th17 response is an important mediator of mucosal immunity against both
extracellular and intracellular pathogens [53]. However, its role in mucosal and systemic
immunity to brucellosis has not yet been clearly defined despite exposure commonly occuring
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through mucosal routes [48, 54, 55]. The Th17 response does not appear to have an important
role in the primary infection of BALB/c or C57BL/6 mice against Brucella spp.; however it has
been shown to be protective in the adaptive response of BALB/c mice vaccinated with RB51 [48,
54, 56]. This is consistent with a study that found vaccinating cattle with Strain 19 or RB51
induces Th17 cells and IL-17 production which peaked one year after vaccination [57]. The
amount of protection an adaptive Th17 response against brucellosis grants varies based on
vaccine, as neutralization of IL-17 with mAb ranges from complete abbrogation to only a slight
reduction in protection [48, 54, 56]. While evidence suggests that a Th17 response is not
necessary for clearance or protection against brucella infection, it is capable of working
synergystically with the Th1 response to enhance protection; and IL-17 compensates to a degree
for a lack of IFN-γ [48, 56].
B CELLS
The effector functions of B cells include antibody production and cytokine secretion [58].
Both BALB/c and C57BL/6 B cell deficient mice clear Brucella bacteria more rapidly than WT
mice through an antibody independent mechanism [37]. Indeed, B cell deficient BALB/c and
C57BL/6 mice produced significantly less TGF-β and IL-10, respectively three weeks post
infection, suggesting that B cells enhance susceptibility to brucella infection through both IL-10
and TGF-β dependent mechanisms [37]. The antibody response to Brucella spp. is protective but
not necessary for immunity [5, 40, 59, 60]. Passive transfer of anti-OPS and anti-outer
membrane protein (Omp) antibodies provide protection to mice against brucellosis [17, 61-67].
However, the rough vaccine strain RB51 does not cause the production of anti-OPS antibodies
[5, 60]. Furthermore, the antibody-mediated protection against membrane proteins is reduced in
smooth strains due to steric hinderance from the OPS of Brucella spp. [63]. Taken together, B
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cells are capable of both a detrimental or beneficial role in the adaptive immune response against
brucellosis.
BRUCELLA ABORTUS VACCINES
It is important to study and refer to the immune responses induced by vaccines known to
provide protective immunity in order to develop more effective vaccines [57]. The mouse model
is the standard model for brucellosis vaccine and immunity research [17]. The information from
this model is not always transferable, but is useful because of the cost and time limitations of
using the target species cattle as a model for B. abortus vaccine research [17, 68]. The B.
abortus live-attenuated vaccines Strain 19 and RB51 are the most widely used vaccines in cattle,
[69] making them good reference vaccines. The current characteristics of an ideal brucellosis
vaccine are: [11, 70].


Live strain capable of inducing a strong Th1 response



Does not induce anti-OPS antibodies that interfere with serological tests



Attenuated and incapable of causing disease or persistence in humans or animals



A single dose induces long-lasting protection against abortion and systemic or
uterine infection



Does not revert to virulence



Does not cause seroconversion on revaccination



Inexpensive and easy to produce and administer

The first vaccine widely used for the control of bovine brucellosis was the live-attenuated
B. abortus Strain 19 [14], which was originally isolated from the milk of a jersey cow by Dr.
John Buck in 1923 [69]. Even though it is effective at controlling brucellosis and inducing
protection that lasts the entire productive lifespan of an animal, there are undesirable
8

characteristics [69]. Some animals remain chronically infected and secrete Strain 19 in milk
[69]. As a smooth strain, Strain 19 induces anti-OPS antibodies which make it difficult to
distinguish from vaccinated and naturally infected animals [69]. Strain 19 also maintains a low
level of virulence, may cause abortion in pregnant cattle, and remains pathogenic to humans
[69].
The characteristics of the immune response induced by Strain 19 are a Th1 biased, IFN-γ
production, antibody production, CD4+ cells, and cytotoxic CD8+ cells in both mice and cattle
[57, 69]. Cattle display memory CD4+, CD8+, and B cells on day 210 post vaccination [57, 71].
In cattle, it was determined that CD4+ cells are the primary source of IFN-γ, while CD8+ cells
didn’t produce significant IFN-γ [57, 72]. Further, no IL-4 was detected and CD4+ cells were
also determined to be the main source of IL-17 [72].
The interference with serological tests and potential for abortion in cattle are the main
reasons Strain 19 was replaced with RB51 [69, 73]. RB51 is a stable rough mutant derived from
B. abortus virulent Strain 2308 passaged on media containing low concentrations of rifampicin
and selecting for rough morphology [69, 74]. As an attenuated rough strain, it does not induce
anti-OPS antibodies and shows reduced colonization in animals [69, 74, 75]. In addition to
cattle, RB51 has been shown to protect water buffalo against B. abortus and protects mice
against B. abortus, B. melitensis and B. ovis [59, 75]. However, RB51 is also pathogenic to
humans, resistant to rifampicin, and not safe for use in pregnant cattle [69].
In both mice and cattle, RB51 induces a strong Th1 response. This includes IFN-γ
production, CD4+ cells, cytotoxic CD8+ cells, and no detectable IL-4 [57, 69]. Similarly to
Strain 19, CD4+ cells are the main source of IFN-γ and IL-17 [49, 57, 76]. It should also be
noted that IL-17 neutralization in RB51 vaccinated mice significantly reduced protection against
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B. melitensis, suggesting an important role for the Th17 response in RB51 induced protection
[77]. Further, passive transfer experiments revealed that CD8+ cytotoxic activity was positively
correlated with IFN-γ levels, suggesting that both T cell subsets are important for optimal
protection [76].
A key difference between the memory cells generated in cattle by RB51 and Strain 19 is
that memory CD4+ and CD8+ cells are induced by both vaccines, but RB51 does not induce
memory B cells indicating the humoral response is not important for protection in cattle [57].
CD8+ cells from RB51 vaccinated cattle are granzyme B+ and perforin+, while Strain 19 CD8+
cells are only granzyme B+ [57]. CD8+ cells that secrete granzyme have cytotoxic activity, and
cytotoxicity via the perforin pathway has been shown to provide protection against B. melitensis
in mice [78, 79].
Passive transfer experiments in mice found that T cells from both RB51 and Strain 19
vaccinated mice protected naïve mice from challenge against B. abortus, although Strain 19
protection was significantly greater than that conferred by RB51 [59]. Further, serum from
RB51 vaccinated mice provided no protection against B. abortus while the Strain 19 vaccinated
mice serum did [59]. The main difference between the immune responses following Strain 19
and RB51 vaccination of cattle can be generalized by stating that Strain 19 is CD4+ directed
while RB51 is CD8+ directed [57]. Further, Th17 and humoral responses appear to enhance
RB51 and Strain 19 induced protection, respectively [40, 77].
CONCLUDING REMARKS: IMMUNOLOGY
A vaccine against brucellosis must induce a strong Th1 immune response, including both
CD4+ and CD8+ cells, to effectively control infection [5, 17, 35-38]. However, the roles of
antibodies, Th2, and Th17 differ between the two commercial B. abortus vaccines, indicating
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that protection against Brucella spp. is best optimized when multiple arms of the immune system
are stimulated [17, 40, 49, 57, 61-63]. Indeed, antibody opsonized Brucella bacteria are more
readily phagocytosized and killed more efficiently in IFN-γ activated macrophages; however a
small number of bacteria survive and replicate in the macrophage [80]. CD8+ cells lyse infected
macrophages and release the intracellular bacteria to be exposed to another round of
opsinization, phagocytosis, and IFN-γ enhanced killing [3, 79, 81, 82]. It is important to balance
these responses when designing a new vaccine. Differentiation of naïve T cells into Th17
requires stimulation by TGF-β, which also downregulates both the Th1 and Th2 differentiation
signalling pathways [26]. However, an adaptive Th17 response has been shown to enhance the
Th1 mediated protection to brucella infection [77]. Th2 cytokines inhibit IL-12 production and
promote antibody production [50, 83]. To achieve maximum protection, a brucellosis vaccine
must sufficiently stimulate a Th2 and Th17 response from the immune system without inhibiting
the development of a Th1 response.
OTHER VACCINATION METHODS
There are currently no ideal vaccine candidates against brucellosis. As stated previously,
the current live-attenuated strains possess safety concerns [69]. Heat-killed Brucella bacteria
and protein subunit vaccines induce lower protection and a Th2 biased response [84, 85]. The
challenge of developing safe brucellosis vaccines capable of stimulating multiple arms of the
immune system may be addressed by using multiple design strategies. DNA vaccination has
been shown to efficiently stimulate both Th1 and Th2 responses, and including multiple epitopes
or epitope dense regions from several antigens induces a broad immune response [15, 85-93]. A
DNA vaccine using six nonamer epitopes from different B. abortus antigens induced a protective
response in the murine model [94]. The overall efficacy may be improved by targeting the
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immune response to conserved and relevant antigens [89, 95-98]. Therefore, a multi-epitope
DNA vaccine against B. abortus may provide increased safety, cross protection, and efficacy
compared to the current live-attenuated vaccines.
DNA VACCINATION
DNA vaccination is an immunization method where a DNA plasmid encoding the desired
antigen is injected into the host, enters host cells, is then expressed endogenously; and the
antigen is secreted from the cell [85, 86]. DNA vaccines are safer than live-attenuated vaccines
which have the possibility of reverting to virulence [15, 85]. They are also simpler to
manufacture, have lower production costs, are less temperature sensitive, and possess a longer
shelf life than most conventional vaccines [15, 85]. A crucial advantage of DNA vaccination is
the ability to stimulate a strong cell-mediated response, Th1 [15, 85, 86]. Additionally, the CpG
oligodeoxynucleotide (CpG) motifs of bacterial DNA serve as an adjuvant that activates
macrophages and dendritic cells, through Toll-like receptor 9 (TLR-9), to secrete IL-12, IFN-γ
and TNF-α [86, 99]. The expressed antigens are processed and presented via both MHC I and
MHC II, which allows both a Th1 and Th2 response to be stimulated [85, 87, 88]. Due to both
the safety and the ability to stimulate Th1 immunity, DNA vaccines are seen as a potential
alternative to the current live-attenuated vaccines against Brucella spp. [15]. DNA vaccination
against brucellosis has been well researched and has shown success in the mouse model [15, 87,
88, 94, 100-108]; however, there is no DNA vaccine against brucellosis in large animals.
DNA vaccines are promising but still have disadvantages. This type of immunization is
limited to protein antigens, may induce tolerance, and the bacteria or parasite antigens are
susceptible to unusual processing [109, 110]. While DNA vaccination in mice has been shown
to be effective, low immunogenicity has been a consistent issue in larger animals, including
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primates and humans [111]. Further, mice often require multiple high doses that cannot be
proportionally applied to large animals [112, 113]. Successful DNA vaccination is also limited
by the transfection rate of target cells and expression rate of the antigen once the DNA enters the
cell [112, 113]. Unprotected DNA is rapidly degraded in the extracellular space, and DNA must
be up taken by the nucleus of host cells to be expressed [112, 113]. Methods to overcome these
limitations exist and are being researched to further improve efficacy of DNA vaccination.
Electroporation and DNA encoding co-stimulatory molecules targeting APCs has been shown to
increase immunogenicity [114]. Further, classical and genetic adjuvants are being researched to
enhance immunogenicity [115].
MULTI-EPITOPE VACCINES
Antigen presenting cells present MHC I and MHC II epitopes to CD8+ and CD4+ cells
respectively [19]. While single epitope vaccinations have been shown to induce protective
immune responses, including multiple epitopes and antigens may result in a more complete
response and increased protection [27, 67, 89, 116-122]. Multi-epitope vaccines are also able to
provide wide population coverage, protect against pathogens with complex life cycles, and
induce cross protection [89, 98, 123-125]. It is possible to simultaneously prime responses to
multiple specific MHC I epitopes with a single MHC II helper epitope [89]. It has been shown
that a single short or long peptide containing intrinsic epitopes with broad MHC binding
potential or MHC I and II epitopes specific for multiple MHC alleles is capable of producing a
strong immune response in all relevant haplotypes of a population [89, 90]. Immunization with
single epitopes, multiple epitopes, and immunodominant regions of antigens has been shown to
provide protection against brucellosis in mice [67, 94, 122].
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EPITOPE INTERACTIONS
The development of both the specific cytotoxic and antibody response is heavily
influenced by CD4+ cell interactions with CD8+ cells and B cells, respectively, indicating that
protection induced by epitope based vaccines is maximized when MHC I, MHC II, and B cell
epitopes are all present [121, 126-129]. Indeed, immunization with MHC II epitopes, also
known as CD4+ ‘helper’ T cell epitopes, has been shown to induce protection against pathogens
and enhance the immune response towards MHC I and B cell epitopes and are therefore
considered to be crucial in the development of epitope based vaccines [89, 116, 117, 121, 126130]. Furthermore, it is not necessary for these epitopes to originate from the same antigen or
pathogen for CD4+ dependent enhancement to occur, which allows for the creation of
multivalent vaccines [116, 117, 127, 129, 131, 132]. A disadvantage of this reliance of MHC II
epitopes is that failure to elicit a sufficient CD4+ T cell response may result in lower
immunogenicity of the vaccine as a whole [133]. The use of promiscuous MHC II epitopes,
regions dense with multiple MHC II epitopes, or long peptide sequences containing multiple
epitopes has been successful at overcoming this issue [90, 92, 121, 128, 129, 134, 135].
Furthermore, optimal CD4+ enhancement of B or CD8+ cell response is achieved when the
epitopes are collinearly linked [89, 116, 127-129].
CROSS PROTECTION
On farms where small ruminants and cattle intermingle, B. melitensis may be transmitted
between the two species; therefore, a vaccine capable of inducing cross protection against
multiple Brucella spp. is desired [136, 137]. Multi-epitope vaccines induce cross protection by
the delivery of several antigens at once or concentrating the immune response on a small number
of conserved epitopes rather than polymorphic epitopes [67, 97, 123, 138-141]. DNA/DNA
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hybridization studies revealed that members of the genus Brucella share over 90% homology
[142], and other studies have shown that immunization with immunodominant conserved regions
of antigens is effective at inducing cross protection [67].
ANTIGENS

Antigen

Protection

IFN-γ

TNF-α

Cytotoxic
CD8+

Cu/Zn
SOD

1.15 - 2.16

+

-

+

BP 26

1.6 - 2.6

+

NA

NA

Omp19

1.38 - 1.85

+

NA

NA

Known protective epitope
Protects bison, immunogenic
in sheep
Mucosal protection,
activates DC, induces IL-17,
protective antibodies

Other Information

Omp16

1.15 -1.97

+

NA

NA

Activates DC, mucosal
protection, induces IL-17,
protective antibodies

Omp25

1.39 - 2.7

+

+

+

Antibodies are protective

L9

1.96 - 2.55

+

+

NA

Protection is CD8+ mediated

L7/L12

0.84 - 1.79

+

+

+

Source
[87, 88,
103, 108,
143-147]
[56, 148,
149]
[39, 53, 54,
67]
[39, 41,
104]
[64, 101,
150, 151]
[15, 152]
[105, 153155]

Table 1.1: Antigen Characteristics
Table of antigens included in the DNA vaccines. Systemic protection induced by the antigen
against B. abortus or B. melitensis was determined by log CFU reduction recovered from spleen
of challenged mice determined at 7-30 days post infection. Characteristics of the immune
response induced by vaccination with the antigen of interest, including IFN-γ and TNF-α
production and induction of specific CD8+ cytotoxic activity. Sources indicate whether the
antigen produces (+), does not produce (-), or if no data was found (NA) with regards to the
characteristic of the immune response.
CU/ZN SUPEROXIDE DISMUTASE
The Brucella spp. express an immunogenic 18.5-20 kDa periplasmic Cu/Zn superoxide
dismutase (SOD) [87, 108, 147], a class of enzymes which allow bacteria to survive the
respiratory burst of phagocytes [156, 157]. B. abortus SOD deletion mutants display reduced
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survival during early infection in vivo [158]. Strain 19 and RB51 vaccinated cattle and mice do
not produce a humoral or cell-mediated immune response against SOD [122, 143], indicating
that SOD is not a necessary antigen for a protective immune response [122]. However,
immunization with SOD has been found to consistently grant protection against brucellosis when
administered in the form of either recombinant peptides, DNA vaccines, whole recombinant
proteins, overexpression mutants, or through co-immunization with other antigens [87, 88, 100,
103, 107, 108, 146, 147].
Mutant strains of RB51 overexpressing SOD (RB51SOD) provided greater protection
than the parental strain in mice, without increased survival or persistence [143, 145, 146]. Only
the RB51SOD vaccinated group produced IFN-γ when splenocytes were stimulated with rSOD
[143]. IgG2a was the only detected antibody isotype against Cu/Zn SOD in RB51SOD
vaccinated mice [143]. Taken together, this indicates that SOD produces a Th1 response when
overexpressed in RB51 vaccinated mice [143]. Another RB51-SOD overexpression mutant
provided significantly greater protection against B. suis in mice than parental RB51 at two weeks
post challenge, indicating SOD is a cross protective antigen [145].
In mice, DNA vaccinations encoding SOD have consistently induced protection at two to
four weeks following challenge and display a Th1 biased immune response characterized by
IFN-γ producing CD4+ cells, specific CD8+ cytotoxic activity, splenocyte proliferation, and low
or no detectable IL-10 and IL-4 [87, 88, 103, 108]. Depending on route of immunization and
dosage, both CD4+ and CD8+ have been observed to be the primary source of IFN-γ [87, 103].
Nasal vaccination with SOD-DNA produces both IgG2a and IgA antibodies as well as CD8+
splenocytes and systemic protection against B. abortus in mice [108]. SOD DNA vaccinated
calves showed significant IgG1 and IgG2a titers and IFN-γ+ peripheral blood monocytes
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(PBMC) but no detectable TNF-α or IL-4 on stimulation with rSOD or crude brucella proteins
[144].
Mice vaccinated with the synthetic SOD peptide GGAPGEKDGKIVPAG, with or
without adjuvant, showed significant protection two weeks following B. abortus challenge [147].
The GGAPGEKDGKIVPAG peptide vaccinated mice produced significant amounts SOD
specific IgG antibodies [147]. Pratt et al. hypothesized that antibody binding to the
corresponding epitope in the whole protein may inhibit SOD function therefore the bacteria will
be more susceptible to the respiratory burst [157]. To our knowledge this has not been tested.
This peptide is not recognized by the humoral or cell-mediated immune response of cattle
vaccinated with Strain 19 or RB51 [122].
BP26
BP26, also known as Omp28 [152], is a 26 kDa periplasmic protein of unknown function
that is immunogenic and immunodominant in cattle, dogs, goats, sheep, and humans [60, 159].
BP26 is highly conserved between B. melitensis, B. abortus, B. ovis, B suis and B. neotomae
[148, 149, 160]. A Strain 19 mutant with the BP26 gene deleted (S19ΔBP26) maintained the
same residual virulence and protection as parental Strain 19 in BALB/c mice and cattle [60,
159], indicating that BP26 is not necessary for protective immunity to brucellosis [60].
However, BP26 is capable of inducing both humoral and cell-mediated responses and is
protective as a subunit or DNA vaccine [56, 149, 160, 161].
Immunization with recombinant BP26 in BALB/c mice resulted in approximately 2.6
logs of protection against B. abortus 10 days post-infection [148]. DNA vaccination with BP26
resulted in 1.16 log less CFU in the spleen of BALB/c mice when challenged with B. melitensis
[149]. Twelve epitopes of BP26 are capable of inducing IFN-γ secretion from PBMCs of sheep
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between 1 to 7.5 months after vaccination with B. melitensis M5-90 [160]. BP26 DNA
vaccination is capable of producing IFN-γ and both specific CD4+ and CD8+ cells in sheep and
bison [56, 160], suggesting this antigen is a candidate for immunization in multiple animal and
Brucella species.
OMP19
Omp19 is an 18-19 kDa outer membrane surface exposed lipoprotein that is associated
with virulence and present in all biovars of the six classical Brucella species [39, 54, 60, 159].
Strain 19 and virulent B. abortus Omp19 deletion mutants are attenuated in mice, do not confer
protection against B. abortus challenge in heifers, and display reduced growth in solid media [60,
159, 162]. Further, CD4+, CD8+ and antibodies specific to Omp19 are capable of inducing
systemic and mucosal protection against brucellosis [39, 67].
Mice immunized with rOmp19 or an immunodominant region of Omp19 (amino acids 21
– 177) display systemic protection against both B. melitensis and B. abortus when challenged
[39, 53, 67]. Monoclonal antibodies against Omp19 protect mice from challenge with the rough
strain B. ovis [39] and bind to heat-killed rough strain RB51 but not smooth strain B. abortus
544. This suggests steric hindrance due to OPS interference with antibodies binding to the
surface exposed Omp19 motifs [39]. However, sera from mice immunized with rOmp1921-177
protected macrophages from cytopathic effects of both B. abortus and B. melitensis in vitro [67],
suggesting that concentrating the antibody response on this region is an effective immunization
strategy.
Splenocytes from both whole rOmp19 and rOmp1921-177 vaccinated mice produce IFN-γ
and IL-12 but not Th2 cytokines on stimulation [39, 53, 67]. The IFN-γ producing cells were
determined to be CD4+ and CD8+ cells; and depletion of either subset reduced, but did not
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completely eliminate, protection against challenge [39]. Recombinant Omp19 has also been
shown to activate dendritic cells and provide mucosal protection against B. abortus [39, 54].
Intragastric (i.g.) immunization of mice with rOmp19 has been shown to induce a Th1 and Th17
response while intraperitoneal (i.p.) vaccination only induced a Th1 response [39, 53, 54]. This
oral protection is Th17 dependent [54].
OMP16
Omp16 is a 16.5 kDa outer membrane surface exposed lipoprotein expressed in all
biovars of the classical Brucella species [39, 104]. No successful Omp16 deletion mutant has
been produced in any of the Brucella spp. [163], suggesting that this protein is necessary for
survival. Omp16 acts as an adjuvant by activating the CD8α+ subset of dendritic cells both in
vivo and in vitro in C57BL/6 mice [41]. This activation is dependent on TLR-4 in vivo but not in
vitro [41].
Vaccination with both Omp16-DNA and rOmp16 induces specific IFN-γ+ splenocytes,
antibodies, and no detectable Th2 cytokines [39, 41, 104]. Monoclonal antibodies against
Omp16 have been shown to provide significant protection in mice against B. ovis challenge [39,
104]. In rOmp16 vaccination, antigen specific CD4+ and CD8+ cells were found to contribute to
the production of IFN-γ; and depletion experiments revealed that both subsets provide significant
protection, but the protection is greatest when both populations are present [39]. Omp16 with
cholera toxin and i.g. immunization of mice provided significant protection at four weeks post
oral challenge with B. abortus similar to RB51 [39, 41]. In summary, vaccination with Omp16
induces a strong Th1, humoral response, and mucosal protection against multiple Brucella spp.
[39, 41, 104].
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OMP25
Omp25 is an immunogenic, surface exposed, 25 kDa transmembrane protein that is
highly conserved [64, 150, 164]. Immunization with Omp25 inconsistently results in TNF-α
production which is contradictory to evidence that Omp25 of B. suis inhibits TNF-α production
in human macrophages and allows secretion of periplasmic proteins in acidic medium [64, 101,
150, 151, 165]. Deletion of Omp25 in Brucella spp. results in lower persistence within the
animal and reveals Omp25 is not necessary for protection against smooth and rough Brucella
spp. in mice or goats [164, 166, 167]. Omp25 is also known to bind the outer membrane to the
peptidoglycan layer [150, 164], which suggests a role in membrane stability, persistence, TNF-α
inhibition, and adaptation to acidic environment. While deletion mutants indicate that Omp25 is
not necessary for protection against Brucella spp., it is still a known protective antigen against B.
abortus and B. melitensis [101, 151].
In sheep, as many as 91% of B. melitensis infected sera contain antibodies to Omp25
[101], indicating that Omp25 is both immunodominant and broadly recognized. Further,
antibodies against Omp25 provide limited but significant protection against B. melitensis [64],
which suggests that a vaccine incorporating Omp25 may induce protective antibodies in a large
percentage of the population.
Mice vaccinated with plasmid DNA encoding Omp25 displayed significant protection
against B. melitensis 15 days post challenge, and no bacteria were recovered from three of five
mice [101]. Splenocytes from mice vaccinated with Omp25 coding plasmid DNA displayed
significant production of IFN-γ and TNF-α, but not IL-4 or IL-10, on stimulation with rOmp25 at
weeks 5, 8, 11 and 21 following initial vaccination [101], indicating that a memory Th1 immune
response was induced. Splenocytes from mice vaccinated with rOmp25 produced significant IL-
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12, IFN-γ, TNF-α, IL-4, and IL-6 on stimulation with rOmp25 [150]. Recombinant Omp25 also
induces in both CD4+ and CD8+ cells cytotoxic killing of infected macrophages [151]. In
conclusion, Omp25 displays several desirable features for a brucellosis vaccine such as the
induction of protective antibodies and a strong Th1 response, including IFN-γ, TNF-α and
specific cytotoxic CD8+ cells [64, 101, 150, 151].
RIBOSOMAL L9
L9 is a conserved 50S ribosomal protein in Brucella spp. [152]. Vaccination with
recombinant or DNA L9 produces IgG isotype one week post vaccination [15, 152]. When
stimulated with rL9, splenocytes from L9 DNA vaccinated mice produced significant quantities
of both IFN-γ and TNF-α. However, IL-2 production was only significant when the DNA
vaccine was introduced through electroporation; and IL-4 was only detected in rL9 + Alum
vaccinated mice [15, 152]. Overall, the IFN-γ producing CD8+ cell population was significantly
larger than the CD4+ population in all groups; and electroporated DNA vaccination induced the
highest CD8+ counts [15]. All groups displayed significant protection against B. abortus 30
days post challenge; however only the electroporated group was comparable to S19 [15, 152].
Together, the data suggests that L9 DNA vaccination induces CD8+ mediated protection against
B. abortus.
RIBOSOMAL L7/L12
The brucella 50S ribosomal subunit L7/L12 is an immunodominant Th1 antigen in both
cattle and mice [153, 168]. Splenocytes from mice vaccinated with Strain 19 proliferate in
response to rL7/L12 but do not produce anti-L7/L12 antibodies [153]. CD4+ PBMCs from cattle
vaccinated with rL7/L12 proliferate in response to recombinant L7/L12 [168], indicating that a
cell-mediated response to this antigen is not species restricted. Without adjuvant, rL7/L12 failed
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to provide protection against B. abortus challenge while rL7/L12 in various adjuvants or L7/L12
DNA vaccination has been shown to provide protection 7 to 30 days post challenge [104, 153155]. Specific cytotoxic CD8+ cells were present in Escheriosome rL7/L12 vaccinated mice, but
no CD4+ cytotoxic activity was detected [153]. Splenocytes from recombinant and DNA
vaccinated L7/L12 mice produced significant IFN-γ and TNF-α and low but significant amounts
of IL-4 when stimulated with rL7/L12 [104, 153-155].
COMBINATION VACCINATION
Immunization with multiple antigens has been shown to effectively enhance protection
against brucellosis. Co-administration of both recombinant and DNA vaccines of B. abortus
BP26 and trigger factor showed greater protection than either did individually [149, 161]. It is
also possible that co-immunization does not increase protection. In mice, rOmp16 + rOmp19
immunization did not significantly alter protection compared to the individual recombinant
proteins against B. abortus challenge [41]. However, immunization with recombinant
immunodominant regions of Omp19 and P39 enhances antibody production and protection
against both B. abortus and B. melitensis compared to immunization with either individual
antigen [67]. Furthermore, Omp16 co-immunized with other antigens enhances protection [104,
169], suggesting that the proper combination of antigens is more important than simply including
more antigens.
A divalent DNA vaccine encoding both L7/L12 and Omp16 induces significantly higher
antibody titers, IFN-γ+ splenocytes, and protection against B. abortus than either univalent DNA
vaccine [104]. Another study found an influenza viral vector expressing L7/L12 and Omp16
provided long term protection against B. abortus and B. melitensis in both pregnant and nonpregnant cattle [169-172]. The immune response consisted of IgG2a dominate isotype, CD4+
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and CD8+ cells, and IFN-γ production [169-172]. This vaccine was found to provide protection
against abortion and heifer and fetal colonization comparable to Strain 19 [170-172]. These
studies indicate that vaccination with the combination of L7/L12 and Omp16 is an effective way
of increasing protection against B. abortus and B. melitensis [104, 171].
A combination DNA vaccine of BCSP31, SOD and L7/L12 provided significantly greater
protection against B. abortus than the univalent DNA vaccines did in mice [100]. IFN-γ
producing CD4+ and CD8+ cells specific to each protein were detected [100]. Protection was
mediated primarily by CD4+ cells but was highest when both subsets were present [100].
Further, both subsets were capable of specific cytotoxic activity, but CD8+ cells displayed higher
activity [100].
Mice co-immunized with recombinant immunodominant regions of Omp19 + P39 were
significantly more protected from both B. abortus and B. melitensis than the univalent groups
[67]. Sera from rOmp19 + rP39 vaccinated mice protected macrophages from cytopathic effects
of B. abortus and B. melitensis in vitro significantly more than either recombinant antigen
individually [67]. Splenocytes from the rOmp19 + rP39 group produced significantly higher
levels of IFN-γ, IL-2, and IL-12 than the univalent groups; and IL-4 was not detected in any
group. Interestingly, the P39 group did not produce detectable IL-12 while the rOmp19 + rP39
produced significantly more than the rOmp19 group. This data suggests an advantage to using
multiple antigens may result in a synergistic effect which induces cytokines an antigen normally
would not stimulate and increases overall stimulation of the immune system [67]. In conclusion,
this study indicates that co-immunization with regions of antigens is capable of increasing both
protection and cross protection against Brucella species.
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The Brucella antigens Cu/Zn SOD, Omp19, Omp16 and L7/L12 have been shown to
induce a strong Th1 response, cross protection and provide higher protection when coimmunized other antigens [67, 100, 104, 145, 171]. Immunization with these antigens has also
revealed other desirable characteristics such as mucosal immunity [39, 54], cytotoxic CD8+
activity [100, 153], protective antibodies [39, 67, 104], and activation of APCs [41]. The
antigens BP26, L9, and Omp25 have not been extensively used in co-immunization studies but
reliably provide high levels of protection [15, 64, 148-152]. Aside from inducing protection and
a strong Th1 response, these antigens are conserved [148, 149, 160, 164], recognized in multiple
animal species [56, 60, 101, 159, 160], induce TNF-α [15, 101, 150], and cytotoxic CD8+
activity [151].
HYPOTHESES AND SPECIFIC AIMS
The overall goal of this project is to design a nonliving vaccine capable of inducing
protection against B. abortus infection. To achieve this, two DNA vaccines p425/BabV1 and
p425/BabV2 were constructed using bioinformatics technology. The hypothesis for this work is
that it is possible to design a DNA vaccine recognized by the humoral immune response of
Brucella abortus Strain 19 vaccinated goats. To test this hypothesis, the following aims were
pursued.
1. The p425/BabV1 and p425/BabV2 were designed and constructed from protective
epitopes.
2. The p425/BabV1 and p425/BabV2 can be transfected into eukaryotic cells.
3. The BabV1 and BabV2 genes are transcribed to RNA.
4. The novel BabV1 and BabV2 proteins may be recognized by sera from Strain 19
vaccinated goats.
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CHAPTER II
MATERIAL AND METHODS
ANTIGEN AND EPITOPE SELECTION
Literature mining was performed to search for known protective antigens and epitopes
from B. abortus. Sequences for the antigens were obtained from NCBI Genbank [173] (Table
2.1). MHC II epitope selection was performed using 15mer binding data from Epimatrix [174]
and IEDB-II [175]. MHC I data was obtained using IEDB-I and Epimatrix to search for
nonamers [175]. The human and bovine MHC alleles used are listed in Table 2.2. RANKPep
was used to predict proper proteasome processing [176]. Overlapping regions of MHC I and
MHC II binding epitopes and known protective epitopes were selected to be included in the
plasmids. Selected epitopes are listed in Table 2.3.

SOD
Omp25
BP26
Omp19
Omp16
L7/L12
L9

Accession
Number
WP_002972093.1
EFH34586.1
WP_006229497.1
EEP62573.1
WP_002966947.1
WP_002964371.1
WP_002963608.1

Table 2.1 Protective B. abortus Antigen Accession Numbers
Table of B. abortus protective antigens and the corresponding NCBI Genbank accession number.
PLASMID CONSTRUCTION
The BabV1 and BabV2 conalbumin signal sequence and open reading frames were codon
optimized for Criteculus griseus and synthesized by Integrated DNA Technologies (IDT,
Coralville, IA). The BabV genes were under the control of CMV Promoter (vector pGWIZ,
Gene Therapy Systems bp 844-899, CTC, 900-918) and contain the conalbumin signal sequence
(Genbank X02009 base pairs (bp) 74-133) [173]. The BabV1 open reading frame contains
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epitopes from SOD, L7/L12, Omp16, and Omp19 with free rotational spacers between epitopes.
The BabV2 open reading frame contains epitopes from SOD, L9, BP26, and Omp25 with free
rotational spacers between epitopes. The free rotational spacers allow the protein to fold in a
way that would produce conformational epitopes similar to the native antigen [177]. The vector
p425 is a heavily modified pBluescript vector and was obtained from laboratory stocks. Plasmid
p425 contains the chicken ovalbumin polyA tail sequence (GenBank Accession #J00895 base
pairs 8260-9175) and a Puromycin resistance gene (pMOD PURO (InvivoGen) bp 717-116).
Human MHC
I Alleles
A0101
A0201
A0301
A2402
B0702
B4403

Bovine MHC I
Alleles
BoLA-1*01901
BoLA-2*01201
BoLA-4*02401
Bola-6*01301
BoLa-3*01701
BoLa-2*00801
BoLa-2*1601
BoLa-1*2301

MHC II
Alleles
DRB1*0101
DRB1*0301
DRB1*0401
DRB1*0701
DRB1*0801
DRB1*1101
DRB1*1301
DRB1*1501

Table 2.2 Selected MHC Alleles
Table of the human MHC I and MHC II alleles and bovine MHC I alleles used to predict
immunogenic epitopes via IEDB I, IEDB II, and Epimatrix.
The pBabV1, pBabV2, and p425 plasmids were digested with Anza restriction enzymes
BshTI and SalI (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. Digested
DNA bands were extracted from a 1% agarose SYBR®Safe gel (Thermo Fisher Scientific,
Waltham, MA) using a razor. Agarose was dissolved and the digested DNA was concentrated
using Zymoclean™ Gel DNA Recovery Kit (Zymo Research, Irvine, CA) according to the
manufacturer’s directions. Digested conalbumin signal sequence and open reading frames of
BabV1 and BabV2 were ligated into the digested p425 using Quick Ligase™ (New England
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Biolabs, Ipswich, MA) according to kit’s recommendation to make p425/BabV1 and
p425/BabV2, respectively.

Antigen
SOD
SOD
SOD
L7/L12
L7/L12
Omp16
Omp16
Omp19
Omp19
L9
L9
BP26
BP26
BP26
Omp25
Omp25

Amino Acid
Position
50-58
75-86
125-149
14-42
52-96
70-99
103-137
79-87
132-163
19-51
108-125
51-79
166-187
230-250
112-138
53-75

Table 2.3 List of B. abortus Epitopes Used in DNA Vaccine Construction
Table of antigens and corresponding amino acid residues predicted to be immunogenic epitopes
by IEDB-I, IEDB-II, Epimatrix, and RANKPep which are included in the p425/BabV1 and
p425/BabV2 vaccines.
Sequences were PCR amplified using the primer sets in Table 3.4 and AccuPrime™
DNA polymerase enzyme and buffer (Invitrogen, Carlsbad, CA) according to manufacturer’s
recommendations. Parameters for PCR were 95°C for 4 minutes then 25 cycles of 95°C for 30
seconds, annealing temperature (Table 2.4) for 30 seconds, 68°C for 45 seconds, and a final
extension segment of 68°C for 5 minutes was performed. Gel electrophoresis was used to
determine the size of the plasmids or PCR products. Briefly, 1% agarose gels containing
ethidium bromide were electrophoresed at 90 mA and UV translumination was used to visualize
the bands. The ladders used were supercoiled ladder (Bayou Biolabs, Metairie, LA) for
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undigested plasmid samples, 1 Kbp (Bayou Biolabs, Metairie, LA) and 100 bp ladders (Bayou
Biolabs, Metairie, LA) for digested plasmids, and 100 bp ladder for PCR products. The products
were sequenced by GeneLab in the School of Veterinary Medicine at Louisiana State University
using the Sanger dideoxynucleotide sequencing method.

Primer Name
BabVpolyA F
BabVpolyA R
BabV1 F
BabV1 R
Conss1 F
Conss1 R
BabV2 F
BabV2 R
Conss2 F
Conss2 R

Sequence 5' to 3'
TAT GGG GGA AAA ATG CAG CCT
CAA TAC GCC CGC GTT TCT T
CAA GCT CAA TGG CTC CAA CG
AGC AAT TGC CTT GTC AGC AT
CGT CGT CGA CAA CAT GAA GC
GCC CTT CTT TGA CC AAT GC
CTA TGA CCG CGA ACA ACG ACG AG
CTG GAG CAG CTT GGT CAT ACA
CGT CGT CGA CAA CAT GAA GC
GTT CGC GAC TGC TCG TTT G

Product Annealing
Length Temperature
(bp)
(°C)
756
53
847

51.5

804

54.8

843

51.5

745

53

Table 2.4 BabV Primer Sets
Table containing the primer sets used to PCR amplify and sequence the BabV1 and BabV2 genes
in p425/BabV1 and p425/BabV2. The primer sets were designed to overlap in a way that
allowed the entire BabV1 and BabV2 genes to be accurately sequenced. Sequence of the forward
and reverse primers, predicted product size in base pairs, and annealing temperature are included.
CELLS AND TRANSFECTION
Plasmids were maintained and replicated in MAX Efficiency® Stbl2™ competent
bacteria (Invitrogen, Carlsbad, CA) incubated at 37ºC. Escherichia coli were transfected with
pBabV1, pBabV2, p425/BabV1, and p425/BabV2 plasmids using the manufacturer’s directions.
Ampicillin was used to select for transfected cells. Plasmids were harvested using
ZymoPURE™ Plasmid Midiprep (Zymo Research, Carlsbad, CA) or Zyppy™ Plasmid Miniprep
(Zymo Research, Carlsbad, CA) kits according to the kit’s recommendations.
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Recombinant proteins were expressed in a Chinese hamster ovary (CHO K1) (ATCC,
Manassas, VA) cell line cultured in Corning® SF media (Corning Inc., Corning, NY)
supplemented with 5% fetal bovine serum, glutamax (Gibco, Grand Island, NY), and incubated
at 37°C with 5% CO2 and humidity. The CHO K1 cells were grown to confluence in T150
flasks then washed with room temperature PBS (Gibco, Grand Island, NY) then passaged using
TrypLE™ Express (Gibco, Grand Island, NY) to disassociate and split cells according to the
manufacturer’s directions into six well plates. CHO K1 cells were transfected 24 hours after
passaging with Lipofectamine™ 3000 (Thermo Fisher Scientific, Waltham, MA) according to
the manufacturer’s instructions. CHO K1 cells transfected with p425/BabV1 and p425/BabV2
are referred to as CHOB1 and CHOB2, respectively. Transfected CHO K1 cells were selected
using media supplemented with 50 µg/ml puromycin 24 hours to allow cells to recover. One
week after transfection, individual clusters were picked with a sterile inoculating loop and
transferred to individual wells. When confluent in the wells, the cloned cells were disassociated
with TrypLE™ Express and transferred to a T25 flask.
When CHOB1, CHOB2, and negative control CHO K1 cells were confluent, the T25
flasks were washed twice with PBS and cultured with Corning® SF media (Corning Inc.,
Corning, NY) supplemented with glutamax (Gibco, Grand Island, NY) and 50 µg/ml Puromycin
(absent in negative control media) and incubated at 37°C with 5% CO2 and humidity. After 72
hours, media was collected and cells were washed twice with PBS. Cells were then
disassociated with TrypLE™ Express and collected in a 15 ml tube. Serum free media and cell
samples were stored at -20ºC until testing.

29

GENOMIC DNA EXTRACTION AND RT-PCR
Genomic DNA was extracted from the CHOB1, CHOB2, and negative control CHO K1
cells using a DNEasy® Blood and Tissue Kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. The BabV1 and BabV2 genes were PCR amplified using the primer
sets listed below (Table 2.5). Parameters for PCR were 95°C for 4 minutes then 30 cycles of
95°C for 30 seconds, annealing temperature (Table 2.5) for 30 seconds, and 68°C for 25 seconds
followed by a final extension of 68°C for 5 minutes. The size of PCR products was determined
via gel electrophoresis procedure as described above. Products were sequenced by GeneLab in
the School of Veterinary Medicine at Louisiana State University using the Sanger
dideoxynucleotide sequencing method.
To determine if the BabV1 and BabV2 genes were transcribed, RNA extraction was
performed using an RNEasy® Plus Micro Kit (QIAGEN, Hilden, Germany) according to the
kit’s recommendations. The RNA sample was immediately used as a template with an OneStep
RT-PCR Kit (QIAGEN, Hilden, Germany) using the primers in Table 2.5. The thermocycler
parameters for reverse transcription and initial PCR activation were 50°C for 30 minutes then
95°C for 15 minutes, respectively. This was followed by 40 cycles of 94°C for 30 seconds,
annealing temperature (Table 3.5) for 30 seconds, then 72°C for 1 minute and a final extension
of 72°C for 10 minutes. The PCR fragments were gel extracted using the Zymoclean™ Gel
DNA Recovery Kit (Zymo Research, Irvine, CA) and sequenced by GeneLab in the School of
Veterinary Medicine at Louisiana State University using the Sanger dideoxynucleotide
sequencing method.
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Primer Name
CHO GADPH F
CHO GADPH R
B1Conss F
B1Conss R
B1BabV F
B1BabV R
B2Conss F
B2Conss R
B2BabV-1 F
B2BabV-1 R
B2BabV-2 F
B2BabV-2 R
BCHOpolyA-1 F
BCHOpolyA-1 R
BCHOpolyA-2 F
BCHOpolyA-2 R

Sequence 5’ to 3’
CGA GAT CCC GCC AAC ATC AA
TGT CAG ATC CAC AAC GGA CAC
ACC GTC GTC GAC AAC ATG AAG
ACT GGG GAT ATC GTT GGA GC
TTC GAT GTT GTC CTT GCC GA
GAA GGC TGC ATT TTT CCC C
GTC GTC GAC AAC ATG AAG CTC
CTC GTT GTT CGC GGT CAT AG
AAA CTA TTG GAC TCG GCC CT
TCC TGC AGT CAA GTA CGG C
CCT GGT GGG AGT CCT GAC AT
GAA TTG CAC CTG CTG TTC TCA CAG T
GTC CCT TCC AAC AAG ACC CA
TCC CTG CTA CAC AAC CTT GC
CCA TTC CTA TGC TGA CAA GGC
CTG GCA CTC TGT TAC CC

Annealing
Temperature
(°C)

Product
Size (bp)
54
501
54
55
694
55
54
920
54
53
636
53
54
485
54
53
730
53
54
676
54
54
688
54

Table 2.5 CHOB Primer Sets
Table of primer sets used during PCR, RT-PCR, and sequencing BabV1 and BabV2 from
genomic DNA and RNA including the 5’ to 3’ sequence of the forward and reverse primers. The
CHO GADPH primer set is specific to a housekeeping gene in CHO K1 cells and used as a
positive control. The primer sets were designed to overlap in a way that allowed the entire
BabV1 and BabV2 genes to be accurately sequenced. The predicted product size in base pairs
and annealing temperature used in the PCR and RT-PCR protocols are included.
SERA AND BRUCELLA ANTIGENS
Sera from B. abortus Strain 19 vaccinated goats was pooled from laboratory stocks
collected from experimentally infected animals (see Appendix B) and diluted 1:7500 in 1%
gelatin solution (TBS/Tween 20%) to make the primary antisera for use in Western blots. The
secondary antibody donkey anti-goat (Abcam, Cambridge, UK) was diluted 1:5000 in 1% gelatin
solution (TBS/Tween 20%). Acetone-killed B. abortus Strain 2308 was acquired from legacy
stocks made prior to 1995 and suspended in water at a concentration of 1 mg/ml.
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WESTERN BLOT
Cell samples were thawed and pelleted by centrifugation at 500g for 10 minutes and
supernatant was then discarded. Cells were resuspended in 5 ml of PBS, and cell counts were
normalized using Volupack tubes (Techno Plastic Products, Trasadingen, Switzerland). Equal
numbers of cells were lysed with M-Per™ Mammalian Protein Extraction Reagent (Thermo
Fisher Scientific, Waltham, MA) according to the manufacturer’s recommendations. Serum-free
media and lysate samples were stored at -20°C until testing.
To prepare samples for Western blot, 15 µl of 2x Laemmli Sample Buffer (Sigma
Aldrich, St. Louis, MO), 10 µl of 10x DTT and 15 µl of serum free media, cell lysate samples, or
B. abortus Strain 2308 antigen were mixed then heated to 100ºC for 10 minutes. The standard
used was Precision Plus Protein™ Dual Color Standards 10-250 kDa (Bio-Rad, Hercules, CA).
Samples were run at 70V for 10 minutes then 200V for 80 minutes in a Criterion™ Precast Gel
(Bio-Rad, Hercules, CA). After electrophoresis was completed, the gel was placed in transfer
buffer (20% methanol in Tris-glycine electrode buffer) for 5 minutes to equilibrate.
Nitrocellulose was rehydrated in transfer buffer for 30 minutes. Electrophoretic transfer
to the nitrocellulose was performed at 25V for 50 minutes. The nitrocellulose membrane was
rinsed with TBS/Tween 20% and the membrane was blocked in TBS/Tween 20% with 5% milk
solution for 1 hour at 37°C in a shaking incubator. The membrane was washed four times with
TBS/Tween 20% for five minutes each wash. Membranes were incubated with the primary
antisera for one hour at room temperature with shaking and then rinsed in TBS/Tween 20% three
times for five minutes per wash. Donkey anti-goat secondary antibody diluted to 1:5000 in 1%
gelatin TBS/Tween 20% was incubated with the membrane at room temperature for one hour
while shaking. The membrane was rinsed and washed with TBS/Tween 20% four times with

32

five minutes per wash then rinsed with distilled water. The color reaction of the membrane was
developed in 1-Step Ultra TMB-Blotting Solution (Thermo Fisher Scientific, Waltham, MA)
until bands appeared, then washed with distilled water and air dried.
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CHAPTER III
RESULTS
PLASMID CONSTRUCTION AND CHO K1 TRANSFECTION
In order to confirm the plasmids were constructed properly, gel electrophoresis was used
to determine if the plasmids, digested DNA, and PCR products matched the expected sizes. The
harvested p425, pBabV1, pBabV2, p425/BabV1, and p425/BabV2 plasmids matched the
expected sizes on gel electrophoresis (Figure 3.1). The products of BshTI and SalI digestion of
the p425, pBabV1, and pBabV2 plasmids were the expected sizes, as well (Figure 3.2).
BabV1/425 and BabV2/425 plasmids were PCR amplified, and the products matched the
predicted sizes (Figure 3.3). The PCR products were sequenced to confirm the correct sequence.
Puromycin successfully selected for transfected CHOB1 and CHOB2 cells. Approximately five
colonies of CHOB1 and CHOB2 cells per well survived after introduction of 50 µg/ml
puromycin to the media. Replicating CHO K1 cells were observed five days post introduction of
puromycin, and no replicating CHO K1 cells were observed in the untreated control wells.

Figure 3.1. BabV Plasmid Gel Electrophoresis
A gel electrophoresis was run on the original 7.) p425 (14,977 bp), 6.) pBabV1 (3,855 bp), and
5.) pBabV2 (3,862 bp). 8.) supercoiled ladder. The p425 with the BabV1 and BabV2 inserts are
referred to as 3-4.) p425/BabV1 (15,277 bp) and 1-2.) p425/BabV2 (15,250 bp) respectively.
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Figure 3.2. BabV SalI and BstHI Digested Samples
A gel electrophoresis was run on the undigested 10.) pBabV2, 12.) pBabV1, and 14.) p425 and
their digestion products with a 15.) 1 Kbp ladder. The restriction enzymes SalI and BstHI were
used to extract the BabV1 and BabV2 inserts from the plasmids and prepare p425 for ligation.
The 11.) BabV1 (1,076 bp) or 9.) BabV2 (1,103 bp) inserts were ligated into digested 13.) p425
(14,179 bp) to make 6 and 8.) p425/BabV1 and 2 and 4.) p425/BabV1, respectively. The
completed 5 and 7.) p425/BabV1 (14,179 and 1,076 bp bands) and 1 and 3.) p425/BabV2
(14,179 and 1,103 bp bands) were digested again to confirm the inserts were present.

Figure 3.3. BabV PCR Gel Electrophoresis
A gel electrophoresis was run on PCR products with a 7.) 100 bp ladder. The entire BabV1 and
BabV2 were PCR amplified from p425/BabV1 and p425/BabV2 respectively with three primer
sets per plasmid. These products were sequenced to confirm the expected sequence. The
products of PCR with template p425/BabV2 and primer set 1.) BabVpolyA (756 bp), 2.) BabV2
(843 bp), and 3.) Conss2 (745 bp). The products of PCR template p425/BabV1 and primer set
4.) BabVpolyA (756 bp), 5.) BabV1 (847 bp), and 6.) Conss1 (804 bp).
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GENOMIC DNA PCR AND SEQUENCING
The gCHOB1, gCHOB2 and negative control gCHO K1 templates, but not the
p425/BabV1 and p425/BabV2 plasmids, produced bands of the predicted sizes when PCR
amplified using the CHO GADPH primer set (Figure 3.4 and Figure 3.5). This primer set is
specific to a house keeping gene in the CHO K1 cells and used as a positive control. Genomic
CHOB1 and plasmid p425/BabV1 templates produced bands of the estimated size when PCR
amplified using the B1BabV primer set (Figure 3.6). The primer sets B1Conss, BCHOpolyA-1,
and BCHOpolyA-2 produced bands of the predicted sizes using gCHOB1 as the template (Figure
3.7). Similarly, gCHOB2 template produced bands of the appropriate size with the B2BabV-1
primer set (Figure 3.6). When gCHOB2 template was used, bands of the predicted base pair
length were produced by the B2Conss, B2BabV-2, BCHOpolyA-1, and BCHOpolyA-2 primer
sets (Figure 3.8). No bands were produced by the gCHO K1 with primer sets above. The PCR
products were successfully gel extracted and confirmed to contain the expected sequence via
Sanger dideoxynucleotide sequencing reaction.

Figure 3.4 CHOB2 Genome PCR 1
A gel electrophoresis was run on PCR products with a 100 bp ladder (5). The GADPH primer
set (501 bp) was used as a positive control to confirm extraction of 1-2.) gCHOB2 DNA and 3.)
gCHO K1. 4.) Plasmid p425/BabV2 was used as the negative control.
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Figure 3.5 CHOB1 Genome PCR 1
A gel electrophoresis was run on PCR products with a 100 bp ladder (7). The GADPH primer
set (501 bp) was used as a positive control to confirm extraction of 2.) gCHOB1 DNA and 4.)
gCHO K1. 6.) Plasmid p425/BabV1 was used as the negative control for the GADPH primer
set. The products of the PCR reaction between primer set B1BabV (920 bp) of 1.) gCHOB1 and
3.) gCHO K1 DNA. The negative control for this primer set was 5.) p425/BabV1.

Figure 3.6 CHOB1 and CHOB2 Genome PCR
A gel electrophoresis was run on PCR products with a 13.) 100 bp ladder. The PCR between
primer set B2BabV-1 (485 bp) and templates 1-5.) gCHOB2 and the positive control 7.)
p425/BabV2 indicates the presence of the BabV2 open reading frame. The negative control 6.)
gCHO K1 for this reaction did not result in a product. The PCR between primer set B1BabV
(920 bp) and templates 9-10.) gCHOB1 and the positive control 12.) p425/BabV1 indicates the
presence of the BabV1 open reading frame. The negative control 11.) gCHO K1 for this reaction
did not result in a product.
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Figure 3.7 CHOB1 Genome PCR 2
A gel electrophoresis was run on PCR products with a 12.) 100 bp ladder. The polyA tail of
BabV1 was confirmed to be present in gCHOB1 using primer sets 1.) BCHOpolyA-2 (688 bp)
and 2.) BCHOpolyA-1 (676 bp). The conalbumin signal was confirmed to be present in
gCHOB1 with the primer set 3.) B1Conss (694 bp). The positive control p425/BabV1 for these
primer sets 5-7.) resulted in products of the expected sizes while the 9-11.) negative control
gCHO K1 DNA did not result in products. Lanes 4.) and 8.) were intentionally left blank.

Figure 3.8 CHOB2 Genome PCR 2
A gel electrophoresis was run on PCR products with a 15.) 100 bp ladder. The polyA tail of
BabV2 was confirmed to be present in gCHOB1 using primer sets 1.) BCHOpolyA-2 (688 bp)
and 2.) BCHOpolyA-1 (676 bp). The BabV2 open reading frame and conalbumin signal were
confirmed to be present in gCHOB2 with the primer sets 3.) B2BabV-2 (730 bp) and 4.)
B2Conss (636 bp). The positive control p425/BabV2 for these primer sets 6-9.) resulted in
products of the expected sizes while the negative control 11-14.) gCHO K1 DNA did not result
in products. Lanes 5.) and 10) were intentionally left blank.
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RT-PCR
RT-PCR was used to determine if the BabV1 and BabV2 genes were transcribed to RNA.
The RT-PCR using B1BabV and B2BabV-1 primer sets resulted in products of the expected
sizes in multiple CHOB1 and CHOB2 RNA templates, respectively (Figure 3.9). The RNA
template from CHOB1 and CHOB2 cells produced bands of the appropriate number of base pairs
with both the CHO GADPH and BCHOpolyA-1 primer sets (Figure 3.10). Furthermore,
CHOB2 RNA produced a band of the predicted size with the B2BabV-2 primer set (Figure 3.11).
The CHO K1 RNA template only produced a band with the CHO GADPH primer set (Figure
3.9, Figure 3.10, and Figure 3.11). Sequencing data confirmed the PCR products contain the
expected sequences.

Figure 3.9 B1BabV and B2BabV-1 RT-PCR on CHOB1 and CHOB2 RNA
A gel electrophoresis was run on RT-PCR products with a 15.) 100 bp ladder. Wells 1-5 are the
products of an RT-PCR with the primer set B2BabV-1 (485 bp) and RNA from multiple CHOB2
cultures. Wells 6-10 are the products of primer set B1BabV (920 bp) and CHOB1 RNA
templates. This indicates that the open reading frames from BabV1 and BabV2 were transcribed
to RNA in the CHOB1 and CHOB2 cells respectively. Lane 11.) was intentionally left blank.
No product was produced by the RT-PCR between negative control CHO K1 RNA and primer
set 12.) B2BabV-1 and 13.) B1BabV. The positive control primer set 14.) CHO GADPH (501
bp) indicates that RNA was extracted from CHO K1 cells.
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Figure 3.10 BCHOpolyA-1 RT-PCR on CHOB1 and CHOB2 RNA
A gel electrophoresis was run on RT-PCR products with a 7.) 100 bp ladder. The CHO GADPH
(501 bp) primer set was used as a positive control to confirm RNA was extracted from 2.)
CHOB2, 4.) CHOB1, and 6.) CHO K1. The RT-PCR with primer set BCHOpolyA-1 (676 bp)
indicates RNA from the polyA tail of BabV1 and BabV2 is transcribed in the 3.) CHOB1 and 1.)
CHOB2 cells respectively. There was no product in the RT-PCR between negative control CHO
K1 RNA and 5.) BCHOpolyA-1.

Figure 3.11 B2BabV2 RT-PCR on CHOB2 RNA
A gel electrophoresis was run on RT-PCR products with a 7.) 100 bp ladder. The CHO GADPH
(501 bp) primer set was used as a positive control to confirm RNA was extracted from 3.)
CHOB2 and 6.) CHO K1. The RT-PCR between CHOB2 RNA and primer sets 1.) B2BabV-2
(730 bp) and 2.) B2BabV-1 (485 bp) indicates RNA from the open reading frame of BabV2 was
transcribed. There was no product in the RT-PCR between negative control CHO K1 RNA and
primer sets 4.) B2BabV-2 and 5.) B2BabV-1.
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WESTERN BLOT
Western blots were performed to determine if the rBabV1 and rBabV2 proteins were
translated and recognized by the humoral immune response of B. abortus Strain 19 vaccinated
goats. The Western blot detected bands at approximately 60 kDa in CHO K1, CHOB1, and
CHOB2 serum-free media samples (Figure 3.12). Bands of varying molecular weights were
detected in the B. abortus Strain 2308 antigen sample (Figure 3.12). Unique bands were not
detected in the CHOB1 and CHOB2 samples as compared to the negative control CHO K1
media samples (Figure 3.12). The Western blot using CHOB1, CHOB2, or CHO K1 samples
cell lysate samples did not detect bands (Figure 3.13). Similar to the previous Western blot,
multiple bands were detected in the positive control B. abortus Strain 2308 antigen (Figure 3.13).

Figure 3.12 Western Blot on Serum Free Media Samples
A Western blot using 1:7500 dilution of sera pooled from B. abortus Strain 19 vaccinated goats
as the primary antibody. Standards are were run in lanes 2.) and 11.). The positive control 1.)
killed B. abortus Strain 2308 antigen indicates the primary antisera is able to detect multiple B.
abortus antigens. Serum free media cultured with non-transfected CHO K1 cells for 72 hours
was used as the negative control (lanes 3. and 12.). The rBabV1 (31 kDa) and rBabV2 (32 kDa)
was not detected in the 5-10.) CHOB1 and 13-18.) CHOB2 serum free media respectively. Lane
4.) was intentionally left blank.
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Figure 3.13 Western Blot on Cell Lysates
A Western blot using 1:7500 dilution of sera pooled from B. abortus Strain 19 vaccinated goats
as the primary antibody. Standards are in lanes 2.) and 13.). The positive control 1.) killed B.
abortus Strain 2308 antigen indicates the primary antisera detected multiple B. abortus antigens.
Cell lysate from non-transfected CHO K1 cells was used as the negative control 3.) and 12.).
The rBabV1 (31 kDa) and rBabV2 (32 kDa) was not detected in the lanes 5-10.) CHOB1 or 1418.) CHOB2 cell lysates respectively. Lane 4.) was intentionally left blank.
DISCUSSION
Brucellosis is a widespread zoonotic disease which causes economic burdens due to
reproductive losses in animals [2, 13]. The current live-attenuated B. abortus vaccines do not
meet the criteria for an ideal vaccine [11, 69, 70, 73] . The goal of this project was to determine
if it is possible to design safe, nonliving vaccines that induce protection against B. abortus. The
method of DNA vaccination was chosen because it is suited for inducing a cell-mediated
immune response, primarily Th1 which is required for resistance to brucellosis [5, 15, 17, 35-38,
85, 86]. Two plasmids were constructed using epitopes from cellular associated antigens known
to induce protection against B. abortus (Table 1.1). These plasmids were transfected into CHO
K1 cells, and selected under puromycin pressure. The PCR on genomic DNA indicated the

42

p425/BabV1 and p425/BabV2 plasmids were successfully transfected into CHOB1 and CHOB2
cells, respectively (Figure 3.4, Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8). The RT-PCR
products and corresponding sequence data indicated the BabV1 and BabV2 genes were faithfully
transcribed to RNA within the CHOB1 and CHOB2 cells, respectively (Figure 3.9, Figure 3.10,
and Figure 3.11). However, Western blots using pooled B. abortus Strain 19 vaccinated goat
sera as the primary antibody did not detect the rBabV1 or rBabV2 proteins either in the media or
cell lysates (Figure 3.12 and Figure 3.13).
The pBabV1, pBabV2, and p425 plasmids were successfully digested indicating the
presence of the BshTI and SalI restriction enzyme sites (Figure 3.2). The approximately 1,000
bp bands from digested pBabV1 and pBabV2 and the approximately 14,000 bp band from
digested p425 were extracted and purified from the SYBR®Safe gel. These digested fragments
contained a conalbumin signal sequence and BabV open reading frame. The fragments were
ligated into the digested p425 which contained the 3’ chicken ovalbumin polyA tail to complete
the BabV1 and BabV2 genes. The newly constructed plasmids p425/BabV1 and p425/BabV2
were shown by gel electrophoresis to be the expected sizes of 15,277 bp and 15,250 bp,
respectively (Figure 3.1). PCR reactions were performed to amplify the inserted region and
polyA tail using three primer sets per plasmid (Table 2.4). The PCR products matched the
expected sizes, and the successful reaction indicated primer binding sites from both the BabV
genes and p425 were present in p425/BabV1 and p425/BabV2 (Figure 3.3). The PCR products
were sequenced, confirming the expected sequence of p425/BabV1 and p425/BabV2, which
includes the conalbumin signal sequence, open reading frames, and chicken ovalbumin polyA
tail. The plasmids were then transfected into CHO K1 cells.
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Following the introduction of 50 µg/ml puromycin to the culture media, approximately
five colonies of CHOB1 and CHOB2 cells survived per well. This indicates that the
concentration of puromycin used is toxic to CHO K1 cells. At five days after the transfection
procedure, replicating cells were observed in the CHOB1 and CHOB2 wells but not in the
untreated control wells. Taken together, this indicates that the puromycin successfully selected
for transfected cells expressing the puromycin resistance gene in p425/BabV1 and p425/BabV2.
The positive control, CHO GADPH, PCR indicated genomic DNA was successfully
extracted from CHOB1, CHOB2, and CHO K1 cells (Figure 3.4 and Figure 3.5). Sequencing
data from PCR products in Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8 confirmed the
conalbumin signal sequence, BabV open reading frame, and polyA tail sequence from
p425/BabV1 and p425/BabV2 were present in gCHOB1 and gCHOB2 DNA, respectively.
These products were not present when the negative control, gCHO K1 DNA, was used as the
template, indicating the control cells were not contaminated.
To determine if the vaccine sequences were being transcribed, RT-PCR was used to
detect BabV1 and BabV2 RNA in the CHOB1 and CHOB2 cells, respectively. The RT-PCR
products from the CHO GADPH primer set reactions with CHOB1, CHOB2, and CHO K1
indicates RNA was successfully extracted from all cultures (Figure 3.9 and Figure 3.10). The
products in Figure 3.9, Figure 3.10 and Figure 3.11 indicate RNA from within the BabV open
reading frame and polyA tail were transcribed in multiple CHOB1 and CHOB2 cell cultures but
not the negative control CHO K1 cells. Sequencing data confirmed the RT-PCR products
contained the expected sequences. Taken together, these data indicate the BabV open reading
frame and polyA tail from the BabV1 and BabV2 genes were faithfully transcribed to RNA in the
CHOB1 and CHOB2 cells, respectively.
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The BabV1 and BabV2 genes contain the conalbumin signal sequence which directs
recombinant proteins to be secreted when expressed in eukaryotic cells [177]. However, no
unique bands were detected using Western blots in the CHOB1 and CHOB2 media compared to
the CHO K1 media (Figure 3.12). Multiple bands were detected by the Western blots in the
positive control, indicating the primary antiserum is capable of detecting B. abortus Strain 2308
antigens. It is possible the proteins are not being secreted despite the secretion signal. In order
to test for this, cells were lysed to extract endogenous proteins for analysis.
A Western blot was performed on cell lysates to determine if the rBabV proteins were
present within the CHOB1 and CHOB2 cells; however, no bands were detected in the CHOB1,
CHOB2, or CHO K1 samples (Figure 3.13). The rBabV proteins should not have been degraded
after lysis because a protease inhibitor cocktail was included in the lysis buffer. However, the
possibility of the proteins being secreted cannot be ruled out. If this is the case, the
concentration of endogenous protein may be below the detectable limits.
It is possible that the concentration of the recombinant proteins in the media and cell
lysates was below the detectable limits of the Western blot. This may be overcome by
concentrating the media and cell lysate samples. Alternatively, increasing the concentration of
the primary antisera may detect the protein at lower concentrations. The concentration of protein
in the samples may be low due to low expression levels of the BabV1 and BabV2 genes. The
RT-PCR used in this study only detected the presence of RNA and not expression levels. A
qPCR would be able to determine the expression levels of the BabV1 and BabV2 genes. In
addition, transfecting a different cell line could increase expression of the proteins.
A limitation of Western blots is the requirement for antibodies that bind to linear
epitopes, which are produced far less than antibodies which bind to conformational epitopes
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[178, 179]. Therefore, using a method which recognizes conformational epitopes, such as
ELISA, may detect the rBabV proteins. It has been reported that the brucella antigens Omp25
and BP26 can be detected by both ELISA and Western blots using serum from naturally infected
or vaccinated animals [101, 180-182]. However, a study using anti-BP26 mAbs indicates ELISA
and Western blot methods are capable of detecting different epitopes [183]. Studies indicate sera
from several animal species that were naturally infected or vaccinated detects Cu/Zn SOD via
Western blot [143, 180, 184, 185]. However, serum from B. abortus infected and Strain 19
vaccinated cows does not detect Cu/Zn SOD via ELISA [122]. This indicates several of the
antigens used to construct p425/BabV1 and p425/BabV2 contain epitopes detectable by ELISA
which cannot be detected via Western blot.
In this study, Strain 19 vaccinated goat sera was used as the primary antibody for the
Western blots in order to determine if the BabV vaccines were recgonized by the humoral
response of a known effective vaccine. However, using sera from animals naturally or
experimentally infected with a virulent strain may be more suitable for detecting the rBabV1 and
rBabV2 proteins. It is known that the antigens recognized by serum from vaccinated and
naturally infected animals differ [186]. Serum from bovines vaccinated with Strain 19 does not
detect BP26 via Western blot or ELISA [60, 187]. Further, Rev 1. and M5-90 vaccinated sheep
produce no or low levels of anti-BP26 antibodies [160, 188]. However, sera from naturally
infected animals detect BP26 via both Western blot and ELISA [160, 188, 189]. Taken together,
this suggests that the rBabV1 and rBabV2 proteins may contain epitopes recognized by antisera
from animals infected with a virulent Brucella spp. but not vaccinated animals.
Sera from Strain 19 vaccinated goats was chosen because polyclonal antibodies binding
to several epitopes would increase the chance of detection over a monoclonal antibody that only
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binds to a single epitope which may not be present in the rBabV proteins. Brucella-infected
sheep sera and murine monoclonal antibodies recognize the BP26 linear epitopes 93-101 and
104-111, which are not present in rBabV2 (Table 2.3) [183]. Furthermore, BP26 amino acids
230-250 have been reported to not be detected by Western blot using sera from B. melitensis and
B. ovis infected sheep [182]. Future research could insert an epitope into the BabV1 and BabV2
genes which binds to a known monoclonal antibody. This could serve as a marker for detecting
the recombinant proteins via Western blot or ELISA.
Another possible reason the Western blots did not detect the recombinant proteins is the
humoral immune response may not be suitable for detecting the rBabV1 and rBabV2. Cellmediated immunity is crucial to protection against brucellosis [5, 17, 35-38]. For this reason, T
cell epitopes were selected and B cell epitopes were not intentionally included in the project
design. The vaccines may not contain epitopes recognized by the humoral response. If this is
the case, the cell-mediated immune response would be more likely to detect the rBabV1 and
rBabV2 proteins. Numerous methods have been developed to detect T cell responses to brucella
antigens. In delayed type hypersensitivity tests, brucella antigen is injected into the skin of
vaccinated or naturally infected animals [40, 190]. If the antigen is recognized by T cells,
inflammation occurs at the site of injection. Alternatively, splenocytes, lymph node tissue, and
PBMCs from vaccinated or infected animals can be stimulated with the antigen of interest [39,
53, 67, 87, 122, 143, 144, 160, 168]. This assay has the advantage of measuring proliferation
and the production of specific cytokines.

47

CHAPTER IV
SUMMARY AND CONCLUSION
SUMMARY
Brucella is a genus of Gram negative, facultative intracellular pathogens which infect
500,000 people each year globally and causes severe economic burdens in developing countries
[1, 2, 12, 13]. The most effective means of controlling brucellosis is vaccination of animals [14,
15]. Live-attenuated vaccines, such as B. abortus Strain 19 and RB51, are used to effectively
control brucellosis in cattle [5, 14]. However, these vaccines are not ideal due to residual
virulence in humans, ability to cause abortion in pregnant cattle, and serological interference
with diagnostic tests [14]. Multiple vaccination strategies have been researched to overcome
these issues.
For a vaccine to be effective against brucella infection a cell-mediated vaccine is needed.
It has been reported that the Th1 immune response must be induced for protection [5, 17, 35-38].
Cytotoxic CD8+ cells are also known to play a role in protective immunity [5, 40]. Heat-killed
and recombinant brucella antigens induce lower protection and a Th2 predominant immune
response [84, 85]. Multiple studies have found DNA vaccination with plasmids encoding
brucella antigens to be a promising immunization strategy [15, 87, 88, 94, 100-108]. In DNA
vaccination, a plasmid encoding the desired antigen is injected into the host, enters the host cell
and is expressed endogenously and secreted from the cell [85, 86]. This allows multiple arms of
the immune system to be induced, such as Th1, Th2, and cytotoxic CD8+ cells, against the
expressed antigens [85, 87, 88]. DNA vaccination is considered to be a safer alternative for
brucellosis vaccination [15]. Furthermore, including multiple antigens or epitopes in a vaccine
has been shown to increase protection against virulent brucella challenge [15, 85-94].
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CONCLUSION
The goal of this research project was to determine if it is possible to design safe,
nonliving vaccines that induce protection against B. abortus. Literature mining was performed
to find known protective antigens. Bioinformatic technologies were used to identify the regions
within these protective antigens most likely to elicit a protective immune response. The DNA
sequence of these regions was used to construct two plasmids for DNA vaccination.
The p425/BabV1 and p425/BabV2 plasmids were transfected into CHO K1 cells and
expressed in order to collect the recombinant protein for analysis. The genome of the transfected
CHOB1 and CHOB2 cells was analyzed using PCR. Transcription of the BabV1 and BabV2
genes to RNA was analyzed using RT-PCR. Finally, the media and cell lysates from transfected
cells were analyzed via Western blot using pooled sera from B. abortus Strain 19 vaccinated
goats.
The PCR and RT-PCR confirmed the CHOB1 and CHOB2 cells were transfected with
and transcribed RNA from the p425/BabV1 and p425/BabV2 plasmids, respectively. However,
the Western blots did not detect rBabV1 or rBabV2 in the media or cell lysate. The antisera used
contains antibodies specific for brucella antigens and should bind to the recombinant BabV
proteins if an epitope is recognized by the humoral immune response of B. abortus Strain 19
vaccinated goats. No protein was detected in the 31 kDa or 32 kDa range for rBabV1 or
rBabV2, respectively. It is possible that the Western blot procedure did not detect the proteins
due to low protein concentration or the primary antisera not recognizing the rBabV1 or rBabV2
proteins. Future studies will need to concentrate the protein, use different antisera, or utilize
ELISA. Another possible route is to use assays which detect cell-mediated immune responses
such as delayed type hypersensitivity or splenocyte assasys.
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APPENDIX A
PROTOCOLS
Anza Restriction Digest (Thermofisher Scientific) Citation [191]
1. Prepare a reaction mix by adding reagents in the order indicated in Table 1.
2. Incubate at 37°C for 15 minutes.
Table 1

Reagent

1 enzyme

2 enzyme

3 enzyme

reaction

reaction

reaction

Nuclease-free water

As required to make up
final reaction volume

Anza 10x Buffer or Anza 10X Red Buffer

2 μL

2 μL

3 μL

DNA

0.2–1 μg

0.2–1 μg

0.2–1 μg

Anza restriction enzyme 1

1 μL

1 μL

1 μL

Anza restriction enzyme 2

—

1 μL

1 μL

Anza restriction enzyme 3

—

—

1 μL

Final reaction volume

20 μL

20 μL

30 μL

Volumes can be scaled up linearly to 5X.
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Zymoclean™ Gel DNA Recovery Kit (Zymo Research) Citation [192]
1. Excise the DNA fragment1 from the agarose gel using a razor blade, scalpel or other
device and transfer it into a 1.5 ml microcentrifuge tube.
2. Add 3 volumes of ADB to each volume of agarose excised from the gel (e.g. for 100 µl
(mg) of agarose gel slice add 300 µl of ADB). Incubate at 37-55 °C for 5-10 minutes
until the gel slice is completely dissolved2.
3. For DNA fragments > 8 kb, following the incubation step, add one additional volume
(equal to that of the gel slice) of water to the mixture for better DNA recovery (e.g., 100
µl agarose, 300 µl ADB, and 100 µl water).
4. Transfer the melted agarose solution to a Zymo-Spin™ Column in a Collection Tube.
5. Centrifuge for 30-60 seconds. Discard the flow-through3.
6. Add 200 µl of DNA Wash Buffer to the column and centrifuge for 30 seconds. Discard
the flow-through. Repeat the wash step.
7. Add ≥ 6 µl DNA Elution Buffer4 or water5 directly to the column matrix. Place column
into a 1.5 ml tube and centrifuge for 30-60 seconds to elute DNA. Ultra-pure DNA is
now ready for use.
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Quick Ligase™ (New England Biolabs) Citation [193]
1. Set up the following reaction in a microcentrifuge tube on ice.
(T7 DNA Ligase should be added last. Note that the table shows a ligation using a molar ratio of
1:3 vector to insert for the indicated DNA sizes.)
Use NEBiocalculator to calculate molar ratios.
COMPONENT

20 μl REACTION

Quick Ligase Reaction Buffer (2X)*

10 µl

Vector DNA (4 kb)

50 ng (0.020 pmol)

Insert DNA (1 kb)

37.5 ng (0.060 pmol)

Nuclease-free Water

to 20 µl

Quick Ligase

1 µl

*The Quick Ligase Reaction Buffer should be thawed and resuspended at room temperature.
2. Gently mix the reaction by pipetting up and down and microfuge briefly.
3. Incubate at room temperature (25°C) for 5 minutes.
4. Chill on ice and transform 1-5 µl of the reaction into 50 µl competent cells. Alternatively,
Store at -20°C.
5. Do not heat inactivate – heat inactivation dramatically reduces transformation efficiency.
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AccuPrime™ DNA polymerase enzyme and buffer (Thermofisher Scientific) Citation [194]
Add the following components to a DNase/RNase-free, thin-walled PCR tube. For
multiple reactions, prepare a master mix of common components to minimize reagent loss and
enable accurate pipetting.
Amount for one 50-µL
reaction
Plasmids/cDNA/l Genomic
DNA
DNA

Component

10X AccuPrime™
PCR Buffer I
10X AccuPrime™
PCR Buffer II
Sense primer (10
µM)

5 µL

—

—

5 µL

1 µL

1 µL

1 µL

1 µL

0.1 pg to 20 ng

10 pg to
500 ng

0.2 µL

0.2 µL

to 50 µL

to 50 µL

Anti-sense primer
(10 µM)
Template DNA
AccuPrime™ Taq
DNA
Polymerase, High
Fidelity
Autoclaved, distilled
water

2. Cap the tube, tap gently to mix, then centrifuge briefly to collect the contents.
3. Place the tube in the thermal cycler, then run the following program:
Step
Temperature
Initial
94°C
denaturation
25–35 cycles of:

Time
15 seconds to 2
minutes

Denature

94°C

15–30 seconds

Anneal

52–64°C

15–30 seconds

Extend

68°C

1 minute per kb
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4. Maintain the reactions at 4°C after cycling. Samples can be stored at –20°C until use.
5. Analyze the amplification products by agarose gel electrophoresis.

54

Invitrogen MAX Efficiency® Stbl2™ Competent cells (Thermofisher Scientific) Citation
[195]
1. Thaw competent cells on wet ice. Place the required number of 17 × 100 mm Falcon®
2059 tubes or similarly shaped polypropylene tubes (see the following note) on ice.
2. Gently mix the cells, then aliquot 100 μL of competent cells into chilled tubes.
3. Refreeze any unused cells in the dry ice/ethanol bath for 5 minutes before returning
them to the −85°C to −68°C freezer. Do not use liquid nitrogen.
4. To determine transformation efficiency, add 5 μL (50 pg) control DNA to one tube
containing 100 μL competent cells. Move the pipette through the cells while dispensing.
Gently tap the tube to mix.
5. For DNA from ligation reactions, dilute the reactions 5-fold in 10 mM Tris-HCl (pH
7.5) and 1 mM EDTA. Add 1 μL of the dilution to the cells (1–10 ng DNA), moving the
pipette through the cells while dispensing the dilution. Gently tap the tubes to mix.
6. Incubate the cells on ice for 30 minutes.
7. Heat-shock the cells 25 seconds in a 42°C water bath; do not shake the cells.
8. Place on the cells ice for 2 minutes.
9. Add 0.9 mL of room-temperature S.O.C. Medium (Cat. no. 15544-034).
10. Shake the tubes containing ligation reaction at 225 rpm (30°C) for 90 minutes.
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ZymoPURE™ Plasmid Midiprep (Zymo Research) Citation [196]
1. Add 8 ml of ZymoPURE™ P1 (Red) to the bacterial cell pellet and resuspend completely
by vortexing or pipetting.
2. Add 8 ml of ZymoPURE™ P2 (Green) and immediately mix by gently inverting the tube
6 times. Do not vortex! Let sit at room temperature for 2-3 minutes. Cells are completely
lysed when the solution appears clear, purple, and viscous.
3. Add 8 ml of ZymoPURE™ P3 (Yellow) and mix gently but thoroughly by inversion. Do
not vortex! The sample will turn yellow when the neutralization is complete and a
yellowish precipitate will form.
4. Ensure the plug is attached to the Luer Lock at the bottom of the ZymoPURE™Syringe
Filter. Place the syringe filter upright in a tube rack and load the lysate into the
ZymoPURE™Syringe Filter and wait 5 - 8 minutes for the precipitate to float to the top.
5. Remove the Luer Lock plug from the bottom of the syringe and place it into a clean 50
ml conical tube. Place the plunger in the syringe and push the solution through the
ZymoPURE™Syringe Filter to clear the debris. Save the cleared lysate!
6. Add 8 ml ZymoPURE™Binding Buffer to the cleared lysate from step 6 and mix
thoroughly by inverting the capped tube 8 times.
Vacuum Protocol
Centrifugation protocol

The vacuum pump should be a
single
or double-staged unit capable of
producing up to 400 mm Hg
pressure.
8. Ensure the connections of the
Zymo-Spin™ III-P Column

A swinging bucket rotor is required for
centrifugation.

8. Remove the 50 ml Reservoir from the top of
the Zymo-Spin™III-P Column Assembly. Ensure
the connection between the 15 ml Conical
Reservoir and Zymo- Spin™ III-P colum nis
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Assembly are finger-tight and
place onto a vacuum manifold.

finger-tight and place the assembly into a 50 ml
conical tube.

9. Add the entire mixture from
step 7 into the Zymo-Spin™ III-P
Column Assembly, and then turn
on the vacuum until all of the
liquid has passed completely
through the column.

9. Add 10 ml of the mixture from step 7 into the
15 ml Conical Reservoir/Zymo-Spin™ III-P
Column assembly, and centrifuge at 500 x g for 2
minutes.

10. Unscrew the purple Luer Lock
cap from the top of the ZymoSpin™ III-P Column and discard
the Reservoirs.

10. Empty the 50 ml conical tube and repeat step
9 until the entire sample has passed through the
column.

Note: Steps 11-12 can also be completed using a microcentrifuge instead of the vacuum manifold
(see full instruction manual).
11. With the vacuum off, add 800 µl of ZymoPURE™Wash 1 to the Zymo-Spin™III-P
Column.Turn on the vacuum until all of the liquid has passed completely through the
column.
12. With the vacuum off, add 800 µl of ZymoPURE™Wash 2to the Zymo-Spin™III-P
Column. Turn on the vacuum until all of the liquid has passed completely through the
column. Repeat this wash step.
13. Place the Zymo-Spin™III-P Column in a Collection Tube and transfer to a
microcentrifuge. Centrifuge at ≥10,000 x gfor 1 minute in order to remove any residual
wash buffer. Transfer the Zymo-Spin™III-P Column into a clean 1.5 ml tube and add
200 µl of ZymoPURE™Elution Buffer directly to the column matrix. Incubate at room
temperature for 2 minutes, and then centrifuge at ≥10,000 x g for 1 minute in a
microcentrifuge.
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Zyppy™ Plasmid Miniprep (Zymo Research) Citation [197]
1. Add 600 µl of bacterial culture grown in LB medium to a 1.5 ml microcentrifuge tube.
2. Add 100 µl of 7X Lysis Buffer (Blue) and mix by inverting the tube 4-6 times. Proceed
to step 3 within 2 minutes.
3. Add 350 µl of cold Neutralization Buffer (Yellow) and mix thoroughly. Invert the
sample an additional 2-3 times to ensure complete neutralization.
4. Centrifuge at 11,000 – 16,000 x g for 2-4 minutes.
5. Transfer the supernatant (~900 µl) into the provided Zymo-Spin™ IIN column. Avoid
disturbing the cell debris pellet.
6. Place the column into a Collection Tube and centrifuge for 15 seconds.
7. Discard the flow-through and place the column back into the same Collection Tube.
8. Add 200 µl of Endo-Wash Buffer to the column. Centrifuge for 30 seconds.
9. Add 400 µl of Zyppy™ Wash Buffer to the column. Centrifuge for 1 minute.
10. Transfer the column into a clean 1.5 ml microcentrifuge tube then add 30 µl of Zyppy™
Elution Buffer directly to the column matrix and let stand for one minute at room
temperature.
11. Centrifuge for 30 seconds to elute the plasmid DNA.
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TrypLE™ Express (Thermo Fisher Scientific) Citation [198]
1. Pre-warmed TrypLE™ and complete growth medium to 37°C before use. Minimize dwell
time.
Note: TrypLE™ may be used at ambient room temperature for many types of cells.
2. Aspirated spent medium and discarded.
3. Washed cell monolayer with 5 mL of Dulbecco’s Phosphate Buffered Saline (DPBS) without
calcium and magnesium. Aspirated and discarded.
4. Added 0.5 ml or 1 ml of TrypLE™ to well or flask, respectively. Ensure complete coverage
of cell monolayer with TrypLE™.
5. Incubated at 37°C until cells have detached. Observe cell monolayer using an inverted
microscope to ensure complete cell detachment from the surface of the flask. Gently tap flask to
dislodge cells if necessary.
6. Added 5–10 mL of pre-warmed complete medium to flask. Tilt flask in all directions to
thoroughly rinse flask. Transfer cell suspension to a 15-mL conical tube.
7. Centrifuged at 100 × g for 5–10 minutes.
8. Discarded supernatant and resuspended cell pellet with 2–5 mL of pre-warmed complete
medium.
9. Seed, incubate and subculture according to normal protocols depending on your cell type.
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Lipofectamine™ 3000 (Thermo Fisher Scientific) Citation [199]
Concentration of plasmid DNA:
BabV1/425 = 1928 ng/µl
BabV2/425 = 2794 ng/µl
Transfection procedure:
1. 3 six well plates were obtained. Labeled CNTL, B1 or B2.
2. CHO K1 cells were split using TrypLE™ and aliquoted into the wells of the plate
3. Cells grown to 70-90% confluency
4. Cells were washed and fed with SF media + 3% FBS + Glutamax before transfection
Per plate:
5. 375 µl of SF media + Glutamax mixed with 11.25 or 22.5 µl of lipofectamine 3000.
Vortexed briefly
6. 750 µl of SF media + Glutamax mixed with 15 µg DNA (7.5 µl BabV1/425 or 5.4 µl
BabV2/425) and 30 µl P3000 reagent. Vortexed
7. High and low concentrations were made by mixing 1:1 ratio of the lipofectamine and
DNA mixtures.
8. Mixture incubated for 10-15 minutes
9. Cells were washed then fed with 250 µl of the final mixture
10. Incubated for 4 days then washed, fed and analyzed for transfection success
11. **no DNA was added to the mixture for CNTL cells
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M-Per Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) [200]
Prior to the procedure, 250 µl of M250 Protease Inhibitor Cocktail, Mamalian (Amresco,
Solon, Ohio) was added to 25 ml M-Per Reagent.
1. Thaw and pellet the cells by centrifugation at 2500 × g for 10 minutes. Discard the
supernatant.
2. Wash the cells once by resuspending the cell pellet in wash buffer (e.g., PBS). Pellet cells by
centrifugation at 2500 × g for 10 minutes.
3. Add 300µl M-PER Reagent to the cell pellet. Pipette the mixture up and down to resuspend
pellet.
4. Shake mixture gently for 10 minutes. Remove cell debris by centrifugation at ~14,000 × g for
15 minutes.
5. Transfer the supernatant to a new tube for analysis.
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DNEasy® Blood and Tissue Kit (QIAGEN) Citation [201]
1. Cultured cells: Centrifuge the appropriate number of cells (maximum 5 x 106) for
5 min at 300 x g. Resuspend the pellet in 200 μl PBS. Add 20 μl proteinase K.
Continue with step 2.
When using a frozen cell pellet, allow cells to thaw before adding PBS until the pellet can be
dislodged by gently flicking the tube. Ensure that an appropriate number of cells is used in the
procedure. Add 4 μl RNase A (100 mg/ml), mix by vortexing, and incubate for 2 min at room
temperature before continuing with step 2.
2. Add 200 μl Buffer AL (without added ethanol). Mix thoroughly by vortexing, and incubate at
56°C for 10 min. It is essential that the sample and Buffer AL are mixed immediately and
thoroughly by vortexing or pipetting to yield a homogeneous solution.
3. Add 200 μl ethanol (96–100%) to the sample, and mix thoroughly by vortexing. It is
important that the sample and the ethanol are mixed thoroughly to yield a homogeneous solution.
4. Pipet the mixture from step 3 into the DNeasy Mini spin column placed in a 2 ml collection
tube (provided). Centrifuge at 6000 x g (8000 rpm) for 1 min. Discard flow-through and
collection tube.
5. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided), add 500 μl
Buffer AW1, and centrifuge for 1 min at 6000 x g (8000 rpm). Discard flow-through and
collection tube.
6. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided), add 500 μl
Buffer AW2, and centrifuge for 3 min at 20,000 x g (14,000 rpm) to dry the DNeasy membrane.
Discard flow-through and collection tube. It is important to dry the membrane of the DNeasy
Mini spin column, since residual ethanol may interfere with subsequent reactions. This
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centrifugation step ensures that no residual ethanol will be carried over during the following
elution. Following the centrifugation step, remove the DNeasy Mini spin column carefully so
that the column does not come into contact with the flow-through, since this will result in
carryover of ethanol. If carryover of ethanol occurs, empty the collection tube, then reuse it in
another centrifugation for 1 min at 20,000 x g (14,000 rpm).
7. Place the DNeasy Mini spin column in a clean 1.5 ml or 2 ml microcentrifuge tube (not
provided), and pipet 200 μl Buffer AE directly onto the DNeasy membrane. Incubate at room
temperature for 1 min, and then centrifuge for 1 min at 6000 x g (8000 rpm) to elute. Elution
with 100 μl (instead of 200 μl) increases the final DNA concentration in the eluate, but also
decreases the overall DNA yield.
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RNEasy® Plus Micro Kit (QIAGEN) Citation [202]
1. Cell samples were thawed and centrifuged at 300 x g for 5 minutes. Supernatant was aspirated
off and discarded.
2. Cells disrupted cells by adding Buffer RLT Plus.
For pelleted cells, loosen the cell pellet thoroughly by flicking the tube. Add 350 μl Buffer RLT
Plus. Vortex or pipet to mix, and proceed to step 3.
3. Homogenized the lysate by vortexing
4. Lysate was transferred to a gDNA Eliminator spin column placed in a 2 ml collection tube
(supplied). Centrifuge for 30 s at ≥8000 x g (≥10,000 rpm). Discarded the column, and saved the
flow through.
5. Added 350 μl of 70% ethanol to the flow-through from step 4, and mixed well by pipetting.
Do not centrifuge. Proceed immediately to step 6.
6. Transferred the sample, including any precipitate that may have formed, to an RNeasy
MinElute spin column placed in a 2 ml collection tube (supplied). Closed the lid gently, and
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm). Discard the flow-through.*
Reuse the collection tube in step 7.
7. Added 700 μl Buffer RW1 to the RNeasy MinElute spin column. Closed the lid gently, and
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard the
flow-through.*
Reuse the collection tube in step 8.
Note: After centrifugation, carefully remove the RNeasy MinElute spin column from the
collection tube so that the column does not contact the flow-through. Be sure to empty the
collection tube completely.
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8. Added 500 μl Buffer RPE to the RNeasy MinElute spin column. Closed the lid gently, and
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard the
flow-through.
Reuse the collection tube in step 9.
9. Added 500 μl of 80% ethanol to the RNeasy MinElute spin column. Closed the lid gently, and
centrifuged for 2 min at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard
the collection tube with the flow-through.
Prepare the 80% ethanol with ethanol (96–100%) and the RNase-free water supplied with the kit.
10. Placed the RNeasy MinElute spin column in a new 2 ml collection tube (supplied). Open the
lid of the spin column, and centrifuge at full speed for 5 min. Discarded the collection tube with
the flow-through.
11. Placed the RNeasy MinElute spin column in a new 1.5 ml collection tube (supplied). Add 14
μl RNase-free water directly to the center of the spin column membrane. Closed the lid gently,
and centrifuged for 1 min at full speed to elute the RNA.
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OneStep RT-PCR (QIAGEN) Citation [203]
1. Thaw template RNA, primer solutions, dNTP Mix, 5x QIAGEN OneStep RT-PCR Buffer, and
RNase-free water, and place them on ice.
2. Prepare a master mix according to the table below.

RNase free water
5x QIAGEN OneStep RT-PCR Buffer
dNTP Mix
F Primer
R Primer
QIAGEN OneStep RT-PCR Enzyme
Mix
Template RNA
Total

Volume
39 µl
10 µl
2 µl
3 µl
3 µl
2 µl
1 µl
50 µl

3. Mix the master mix thoroughly, and dispense appropriate volumes into PCR tubes. Mix
gently, for example, by pipetting the master mix up and down a few times.
4. Add template RNA (≤ 2 μg/reaction) to the individual PCR tubes.
5. Program the thermal cycler according to the program outlined in the table below.
Reverse
Transcription
Initial PCR
activation
3 Step cycling
Denaturation
Annealing
Extension
Number of cycles
Final extension

30 minutes

50°C

15 minutes

95°C

30-60 seconds
30-60 seconds
1 minute
25-40 cycles
10 minutes

94°C
50-68°C
72°C
72°C

6. Start the RT-PCR program while PCR tubes are still on ice. Wait until the thermal cycler has
reached 50°C. Then place the PCR tubes in the thermal cycler.
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APPENDIX B
PILOT STUDY USING BRUCELLA ABORTUS STRAIN 19 AS A MODEL FOR
VIRULENT CHALLENGE IN GOATS
Brucella is a genus of Gram negative, facultative intracellular pathogens named for their
natural hosts with B. melitensis for goats and B. abortus for cattle [1, 5]. Infected cattle abort
during the last trimester of pregnancy and secrete Brucella in milk [2, 68]. Human exposure
occurs through unpasteurized milk, blood, lymph or tissues from infected animals and may result
in undulant fever, arthritis, endocarditis, and spondylitis [2-4, 6, 11]. Globally, there are
approximately 500,000 cases of human brucellosis reported each year and high economic
burdens due to animal brucellosis in developing countries [12, 13]. In the United States, there
are limited means of controlling brucellosis in wildlife reservoirs which are capable of spreading
infection to domestic livestock [17, 204].
Vaccination has proven to be effective in controlling brucellosis; however, further
research is necessary to develop an ‘ideal’ vaccine [11, 14, 15, 69, 70]. While the mouse is the
standard animal model for brucellosis vaccine development, results are not always applicable to
the target species, such as cattle [17]. The caprine model has the advantage of using both a
ruminant and natural host for Brucella spp. [68]. Goats infected with B. abortus develop similar
clinical signs and serological response as cattle [205]. Goats are also less costly to maintain and
have shorter gestation lengths than large ruminants [68]. Vaccine development is further
complicated because the challenge strain B. abortus 2308 is a select agent, which is subject to
strict regulations [206]. A possible solution to this obstacle is using Brucella spp. that are
exempt from these regulations as the challenge, such as Strain 19 [207].
The first widely used vaccine against bovine brucellosis in the U.S. was the liveattenuated B. abortus Strain 19, which provides protection for the entire productive life span of
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the animal [14, 69]. In domestic cattle, vaccination with Strain 19 combined with test and
slaughter policies has been effective in controlling brucellosis in several countries [208, 209].
While less protective, it can be used in wildlife control plans, as well [210-213]. Despite these
benefits, Strain 19 has many negative qualities. Vaccination with Strain 19 interferes with
serological tests, which led to it being replaced by Strain RB51 in the United States [69, 73].
Strain 19 also maintains a low level of virulence, may cause abortion in pregnant cattle,
and remains pathogenic to humans [69]. Vaccination with Strain 19 is also known to cause
orchitis and can be isolated from testicles of bulls [214, 215]. Though it is rare, some cattle
remain chronically infected and excrete Strain 19 in milk [69, 209, 216]. The rate of chronic
infection and abortion is higher in bison, which limits its use in wildlife control plans [212].
It is known that goats abort and bacteria can be isolated from milk and fetal tissues when
vaccinated with B. melitensis Rev. 1, another live-attenuated strain, during late pregnancy [217220]. Furthermore, abortion rate and shedding increases in a dose dependent manner with higher
doses of Rev. 1 [219]. Due to its residual virulence and ability to infect ruminants other than
cattle, we hypothesize that a sufficient dose of Strain 19 may mimic virulent challenge in both
non-pregnant and pregnant goats.
MATERIALS AND METHODS
STRAIN 19 AND BACTERIAL CULTURE
Brucella abortus Strain 19 was obtained from laboratory stocks originally from the
USDA and kept at -80°C. Bacteria were grown on Schaedler agar (Remel, San Diego, CA) with
Brucella Selective Supplement (Oxoid Inc, Nepean, ON) and 5% Horse serum (Sigma Life
Science, St. Louis, MO) and incubated at 37°C with 5% CO2 and humidity. Inoculation doses of
Strain 19 were grown on the plates then collected by washing with PBS and pipetting off the
liquid into vials. The vials were confirmed to contain 1X1011 colony forming units (CFU)/ml by
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serial dilution. Vials were snap frozen and stored at -80°C until time of infection. Before
infection, vials were thawed and diluted in PBS to the appropriate concentrations and CFU/ml
confirmed by serial dilutions.
GOATS
All goats were bled, Card tested, and dewormed prior to infection. For the transient
colonization study, eight breeding age female Boer goats were housed at the Agriculture Center
Isolation Facility (ACIF, Baton Rouge, LA) and acclimated for two weeks before infection.
Goats were infected with either 1X109 or 1X1010 CFU by placing 50 µl inoculum in each
conjunctival sac. At two and four weeks post infection, two goats from each group were
sacrificed by captive bolt and exsanguination. Blood, parotid lymph node, prescapular lymph
node, internal iliac lymph node, supramammary lymph node, liver, and spleen samples were
taken at the time of sacrifice. Tissue samples were stored at -20°C until testing.
All goats were bled, Card tested and dewormed prior to infection and exposure to bucks.
Does were exposed to two bucks for 60 days. Pregnancy status and gestation length were
confirmed by ultrasound. Thirteen pregnant does were housed at ACIF and acclimated for two
weeks prior to infection at approximately 100 days gestation. The treatment groups (4 goats
each) were infected with either 1X109 or 1X1010 CFU via 50 µl inoculum in each conjunctival
sac (CJ). The positive control group (5 goats) was infected with 1X107 CFU via intravenous
(IV) injection. Goats were monitored twice a day, and parturition status was recorded as live or
dead. Kids were euthanized by CO2 asphyxiation and exsanguination immediately after
parturition. Fetal lung, spleen and abomasal fluid samples were collected and stored at -20°C
until testing. Milk samples were taken 2-4 weeks post-parturition and stored at -20°C until
testing. Maternal blood samples were taken at 2-4 weeks and 4-6 weeks post parturition.
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SERA, MILK AND TISSUE SAMPLES
Blood samples were allowed to clot at room temperature then centrifuged at 3400g, and
sera was pipetted off and stored at -20°C until testing. Card tests were performed on sera
samples to determine serological status. Lymph node, spleen and liver samples were thawed;
and ground with a Bullet Blender 50 (Next Advance, Averill Park, NY); and 100 µl aliquots
were plated. Aliquots of abomasal fluid and milk were plated (100 µl). Fetal lung samples were
tested for bacteria by blotting. Briefly, lung samples were dipped in 70% ethanol then blotted
dry on sterile gauze. Lung tissue was cut with sterile scissors and the exposed tissue pressed
against the Schaedler agar. Final CFU/ml and CFU/gram of tissue were determined after three
weeks of incubation.
BRUCELLA IDENTIFICATION
Suspected B. abortus Strain 19 colonies were confirmed by Gram stain, colony
morphology, oxidase, catalase, urease, H2S and TSI biochemical tests.
STATISTICS
Statistical analysis was not used because this was a pilot study, and numbers were kept
small.
RESULTS
TRANSIENT COLONIZATION
All goats were Card negative pre-infection. Post-infection, one goat challenged with
1X109 CFU was Card negative while all others tested positive (Table 3). At 14 days post
infection, Strain 19 was isolated from all lymph node, spleen, and liver samples of the 1X1010
group, while the 1X109 group only displayed bacteria in the parotid lymph node (Table 1 and
Table 2). At 28 days post infection, one goat in the 1X109 group was colonized in all tissue
samples taken, while the other goat in the group only had Strain 19 recovered from the parotid
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lymph node. In the 1X1010 group, the prescapular lymph node, supramammary lymph node, and
spleen were colonized in only one goat (Table 2).

1X109

Par

SM

PS

II

Spl

LV

14 days

250 (2.40)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

14 days

121.28 (2.08)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

28 days

287.88 (2.46)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

28 days

7320.2 (3.86)

225.42 (2.35)

95.32 (1.98)

109.2 (2.04)

108.69 (2.04)

28.27 (1.45)

Table 1.
CFU/g (Log/g of tissue) of B. abortus Strain 19 recovered from tissue of goats infected with
1X109 at 14 and 28 days postinfection. Parotid lymph node (Par), Prescapular lymph node (PS),
supramammary lymph node (SM), internal iliac lymph node (II), spleen (Spl), and liver (LV)
samples.
1X1010

Par

PS

SM

II

Spl

LV

14 days

9223.3 (3.96)

84.82 (1.93)

143.94 (2.16)

120.25 (2.08)

8520.18 (3.93)

0 (0)

14 days

2900.76 (3.46)

201.7 (2.3)

246.75 (2.39)

226.19 (2.35)

1187.5 (3.07)

23.17 (1.36)

28 days

604.05 (2.78)

0 (0)

0 (0)

0 (0)

27.14 (1.43)

0 (0)

28 days

7587.86 (3.88)

791.67 (2.90)

284.43 (2.45)

0 (0)

0 (0)

0 (0)

Table 2.
CFU/g (Log/g of tissue) of B. abortus Strain 19 recovered from tissue goats infected with 1X1010
at 14 and 28 days postinfection. Parotid lymph node (Par), Prescapular lymph node (PS),
supramammary lymph node (SM), internal iliac lymph node (II), spleen (Spl), and liver (LV)
samples.
14 days
1X10

9

1X1010

28 days

50%

100%

100%

100%

Table 3.
Percent of Card positive nonpregnant goats at 14 and 28 days postinfection with 1X109 or
1X1010 CFU of B. abortus Strain 19.
PREGNANT CHALLENGE
All does were Rose Bengal card test negative prior to infection. Table 4 shows the
serological status of the does at 2-4 and 4-6 weeks post parturition. Sonograms were used to
estimate gestation length within 21 days. Average gestation lengths (Table 5) are within 21 days
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of the average 150 days of normal caprine gestation. All kids were born alive; and no Strain 19
was recovered from any of the milk, fetal lung, fetal spleen, or abomasal fluid samples (data not
shown).
CJ 109
2-4 weeks
4-6 weeks

CJ 1010

50%
50%

75%
66%

IV 107
50%
50%

Table 4.
Percent Card positive at 2-4 and 4-6 weeks post parturition. Goats were infected at
approximately 100 days gestation with B. abortus Strain 19 either conjunctively (CJ) or
intravenously (IV).

1X109 CJ
1X1010 CJ
1X107 IV

Average
Gestation
Length (Days)
129.25
133.25
129.25

Table 5.
Estimated gestation length based on sonograms. All groups are within the normal gestation
length of 150 days for caprine pregnancy.
DISCUSSION
The transient colonization study performed suggests that Strain 19 colonization is
consistent with the profile of an attenuated mutant in the caprine model [68]. The liver, spleen,
and all lymph nodes were colonized by 14 days post infection in the 1X1010 CFU group (Table
2). In contrast to virulent Brucella strains [68], Strain 19 was clearing from the animal by 28
days post-infection (Table 2). The lower dose, 1X109 CFU, disseminated slowly and was only
detectable beyond the parotid lymph node in one goat sacrificed at 28 days post infection (Table
1). All animals except one were Card positive at time of sacrifice (Table 3). The Card negative
animal was from the 1X109 CFU group sacrificed at 14 days post inoculation, and Strain 19 had
not disseminated to tissues beyond the parotid lymph node.
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The virulent challenge B. abortus caprine model produces consistent results in pregnant
goats; 30-50% abort and 50-70% dam kid pair colonization [68]. Further, goats infected with B.
abortus 2308 during the third trimester of pregnancy shed bacteria in milk [221]. The Card test
indicates that 50-75% of the pregnant goats were transiently colonized by Strain 19 (Table 4).
However, the conjunctival and intravenous challenge with attenuated Strain 19 resulted in no
abortions; and bacteria was not recovered from milk, fetal tissue, or abomasal fluid samples
(Table 4 and Table 5).
The inability of B. abortus Strain 19 to induce abortion might be due to infection
occurring in a non-native host. It has been shown that B. abortus induces less lesions in pregnant
goats than pregnant cows [222]. Furthermore, virulent B. melitensis challenge results in both
higher abortion (70-100%) and dam kid pair colonization (90-100%) rates than B. abortus in the
caprine model [68]. Based on previous research, the live-attenuated vaccine B. melitensis Rev. 1
persists in goats longer than B. abortus Strain 19 [223]. Three weeks after vaccination, Rev. 1
can be isolated be the spleen, liver and systemic lymph nodes and begins to clear between weeks
three and five. The bacteria persist only in the prefemoral and prescapular lymph nodes after
eight weeks [223]. Despite not being directly comparable, our data suggests that B. abortus
Strain 19 and B. melitensis Rev. 1 are in a similar stage of clearance from the goat at four and
eight weeks post infection, respectively [223] (Table 4 and Table 5).
The intravenous inoculation route immediately induces bacteremia in the animal,
suggesting that Strain 19 was not able to cross the caprine placenta or crossed the placenta but
failed to colonize the fetus. Studies indicate that complications due to Strain 19 vaccination in
cows are rare. The vaccine strain induces abortion and is shed in the milk of only 1-5% and
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1.9% of vaccinated cows, respectively [224-227]. Our results suggest that Strain 19 is similarly
attenuated in the caprine model.
CONCLUSION
Animal brucellosis causes high economic burdens and infects over half a million people a
year worldwide [12, 13]. Development of improved vaccines is limited by regulations on the
virulent strains of Brucella spp [206]. The purpose of this study was to determine if the liveattenuated vaccine Strain 19 could mimic a virulent B. abortus challenge in the caprine model.
Transient colonization was established in non-pregnant goats, with the higher inoculation dose
disseminating more rapidly and bacteria clearing from the animals by 28 days post challenge
(Table 1 and 2). Pregnant goats challenged with Strain 19 did not abort; and no bacteria were
recovered from milk, fetal lung, spleen, or abomasal fluid. This suggests that B. abortus Strain
19 is not able to act as a virulent challenge in pregnant goats.
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